EP2588157A1 - Lipidbeschichtung für medizinische vorrichtungen zur fresetzung bioaktiver wirkstoffe - Google Patents

Lipidbeschichtung für medizinische vorrichtungen zur fresetzung bioaktiver wirkstoffe

Info

Publication number
EP2588157A1
EP2588157A1 EP11733953.1A EP11733953A EP2588157A1 EP 2588157 A1 EP2588157 A1 EP 2588157A1 EP 11733953 A EP11733953 A EP 11733953A EP 2588157 A1 EP2588157 A1 EP 2588157A1
Authority
EP
European Patent Office
Prior art keywords
coating
agent
bioactive agent
expandable
lipid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP11733953.1A
Other languages
English (en)
French (fr)
Other versions
EP2588157B1 (de
Inventor
Ralph A. Chappa
Emily R. Rolfes Meyering
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Surmodics Inc
Original Assignee
Surmodics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Surmodics Inc filed Critical Surmodics Inc
Publication of EP2588157A1 publication Critical patent/EP2588157A1/de
Application granted granted Critical
Publication of EP2588157B1 publication Critical patent/EP2588157B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/08—Materials for coatings
    • A61L29/085—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/04—Macromolecular materials
    • A61L29/044—Proteins; Polypeptides; Degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A61L29/145—Hydrogels or hydrocolloids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A61L29/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/10—Balloon catheters
    • A61M2025/1043—Balloon catheters with special features or adapted for special applications
    • A61M2025/105—Balloon catheters with special features or adapted for special applications having a balloon suitable for drug delivery, e.g. by using holes for delivery, drug coating or membranes

Definitions

  • the present invention relates to a lipid coating on an expandable and collapsible structure of a medical device and methods of making and using these coatings and devices.
  • a coating including one or more lipids can increase the amount of therapeutic agent released from the device at the delivery site.
  • drug released from an implanted medical device has been shown to be beneficial for the function of devices and the treatment of various medical conditions.
  • delivery of a drug from the device surface can prevent cellular responses initiated by the presence of the implantable device.
  • drug released from the device can prevent conditions that would otherwise shorten the functional life of the device following implantation.
  • Drug released from the device may also be directed at treating a diseased area of the body.
  • Some implantable devices simply have a drug applied to the device surface. Such preparations are generally undesirable because the drug can be easily removed from the surface during insertion. In addition, release of the drug is generally difficult to control following implantation.
  • Implantable medical devices having thin polymeric coatings containing therapeutic compounds have been described in the art and provide improvements for protecting and controlling the release of drug from the device surface. Some of these coatings are capable of releasing drugs to provide a local therapeutic effect in the vicinity of the implanted device. Such devices have been shown to be particularly valuable for the treatment of diseases of the cardiovascular system.
  • Drug-eluting stents can provide localized release of a therapeutic substance at the site of administration. Local administration of therapeutic agents via polymeric coatings on stents has shown favorable results in reducing restenosis.
  • Several classes of polymer chemistries have been explored for use in drug-releasing coatings for stent as found in current art, some of which have been approved and are currently being used in medical procedures. Many of these chemistries are useful for delivering hydrophobic drugs.
  • these polymer systems may not be ideal.
  • some applications involve the transient insertion of a medical device to a target tissue in the body.
  • the rate of release of drug from such a polymer system may not be sufficient to provide a therapeutic amount of drug to the target tissue.
  • the present invention relates to a lipid coating for medical devices including an expandable and collapsible structure and methods of making and employing them.
  • a coating including one or more lipids increases the amount of therapeutic agent released from the device at the delivery site.
  • the present invention relates to a medical device including a lipid layer.
  • This medical device can also include an expandable and collapsible structure and an agent coating on the expandable and collapsible structure.
  • the agent coating includes a bioactive agent.
  • the lipid coating is on the agent coating.
  • the lipid coating can have a melting or softening point greater than room temperature and less than body temperature of the subject. This device is effective for delivering the bioactive agent to a site within a subject.
  • the medical device is a balloon catheter.
  • This balloon catheter includes a balloon and an agent coating on the balloon.
  • the agent coating includes a bioactive agent.
  • the device also includes a lipid coating on the agent coating.
  • the lipid coating can have a melting or softening point greater than room temperature and less than body temperature of the subject. This balloon catheter is effective for delivering the bioactive agent to a site within a subject.
  • the present invention also includes a method of delivering a bioactive agent to a site in a subject, the method employing the present medical device.
  • the method can include providing the present medical device and inserting the medical device into the subject.
  • the method can also include expanding the expandable and collapsible structure at the site in the subject to contact a tissue at the site with the agent coating, the lipid coating, or both coatings to release bioactive agent to the tissue.
  • Figure 1 schematically illustrates coatings on an expandable and collapsible structure.
  • Figure 2 illustrates that the present lipid coating significantly decreased release of particles from a coated catheter balloon in simulated use testing.
  • Figure 3 illustrates that the present lipid coating increased transfer of drug to tissue as well as decreasing loss of drug in ex vivo testing.
  • the present invention relates to a medical device that delivers a bioactive agent to a site within a subject.
  • the present invention also relates to methods of making and using the present device.
  • At least a portion of the medical device can be inserted into the subject.
  • the portion of the medical device that can be inserted into the subject includes an expandable and collapsible structure.
  • the expandable and collapsible structure is a balloon of a balloon catheter.
  • the device includes a coating including a bioactive agent (an agent coating).
  • the device also includes a lipid coating on all or part of the coating including the bioactive agent.
  • the lipid coating can provide one or more of several advantageous characteristics to the medical device.
  • the lipid coating can, for example: 1) protect an underlying coating that includes a bioactive agent (e.g., the agent coating); 2) serve as a lubricant (e.g., a sacrificial lubricant) as the device contacts a subject's tissue; 3) provide a deformable hydrophobic matrix that further enhances delivery to a hydrophobic tissue or surface thereof (e.g., the walls of a blood vessel); 4) provide a matrix that maintains the structural integrity of the assembled coatings and bioactive agent beneath (e.g., hold things together); or more than one of these characteristics.
  • a bioactive agent e.g., the agent coating
  • a lubricant e.g., a sacrificial lubricant
  • the lipid coating is solid (e.g., waxy) or semi-solid at room temperature and soft or liquid at the body temperature of a subject.
  • the lipid coating can be or include a lipid or mixture of lipids that is solid at room temperature and liquid at 37 °C and forms a coating that protects an underlying coating including a bioactive agent.
  • a mixture of 50 wt-% oleic acid and 50 wt-% dodecanoic acid is such a coating composition.
  • the present lipid coating can increase the amount of bioactive agent that is delivered to a tissue after a balloon catheter is put through a tortuous path.
  • the lipid coating is solid at room temperature but softens or melts (e.g., liquefies) when exposed to the subject's body temperature.
  • the barrier layer is solid at room temperature but softens or melts as the coated portion of the device makes its way through the subject to the site at which the bioactive agent is to be delivered (the delivery site).
  • the barrier layer can be made of or include a composition that has a melting or softening point that is greater than room temperature and less than the subject's body temperature.
  • the softening or melting can occur as the coated portion of the device makes its way to the delivery site, the melting or softening can occur at the delivery site, or both.
  • the softening, softened, melting, or melted lipid composition can leave the medical device, the portion of the medical device with the coating including the bioactive agent, or both as the coated portion of the device makes its way to the delivery site, at the delivery site, or both.
  • the lipid coating can increase the amount of bioactive agent that is delivered to a desired location in a subject when the medical device is inserted into the subject.
  • the solid or semi-solid lipid coating can protect or isolate the coating including the bioactive agent during handling of the medical device outside the subject, as the coated portion of the device makes its way through the subject to the site at which the bioactive agent is to be delivered, or both. That is, the solid or semi-solid lipid coating can reduce the degree to which the coating including the bioactive agent is contacted by the atmosphere, by handling, by a guide catheter or other medical device, by tissue, by bodily fluids, or by a plurality thereof before the coated portion of the device arrives at the site at which the bioactive agent is to be delivered. This reduced contact can increase the amount of bioactive agent that is delivered at the desired site.
  • Such a lipid coating has protected the underlying agent coating.
  • the solid or semi-solid lipid coating can reduce friction from the device or the underlying coatings contacting a guide catheter, tissue, or fluid. Such lubricating can result in an increase the amount of bioactive agent that is delivered at the desired site. As the medical device makes its way to the delivery site, the lipid coating may be removed from the device as it lubricates. That is, the lipid coating can be a sacrificial lubricant.
  • the lipid coating increases the structural integrity of the coatings and bioactive agent on the device.
  • a solid or semisolid lipid coating can prevent or reduce the incidence of microparticles or portions of microparticles of active agent becoming dislodged from the device as it makes its way to the delivery site or as it is handled by medical personnel.
  • the lipid coating can be viewed, for example, as a viscous matrix or an adhesive matrix that holds together these various coatings and particles as the medical device makes its way through a tortuous path to the delivery site.
  • the lipid coating can be viewed, for example, as a viscous matrix or an adhesive matrix that holds together these various coatings and particles as the medical device contacts vessel walls or other tissue as it makes its way to the delivery site.
  • the lipid coating may be removed from the device as it protects. That is, the lipid coating can serve as a sacrificial protectant.
  • a medical device including the present lipid coating can include a structure (e.g., a substrate) on which is disposed a coating (e.g., an agent coating) including a bioactive agent.
  • a coating e.g., an agent coating
  • the agent coating can be merely bioactive agent that has been deposited upon or adhered to the substrate.
  • the agent coating can be a polymer matrix containing or immobilizing the bioactive agent.
  • the lipid coating can be
  • a major portion of the lipid coating is gone from the portion of the medical device bearing the coating including the bioactive agent when it arrives at the delivery site. That is, when the portion of the medical device with the coating including the bioactive agent arrives at the delivery site there remains an insufficient amount of the lipid coating composition to separate bioactive agent from the subject's tissue.
  • a major portion of the lipid coating is gone from the portion of the medical device with the coating including the bioactive agent when the bioactive agent is delivered to the subject's tissue at the delivery site. That is, for and during delivery of the bioactive agent there remains an insufficient amount of the lipid coating composition to separate the bioactive agent from the tissue. With a substantial portion of the lipid coating composition removed from the coating including the bioactive agent, the bioactive agent can be released from the coating and transferred to or taken up by (or both) the tissue at the delivery site.
  • expanding the coated portion of the medical device increases the surface area of this portion of the device and decreases the thickness of (i.e., thins) the coating of the softened or melted lipid coating composition. It is possible that the decreased thickness or thinning of the lipid coating composition is sufficient for allowing release of the bioactive agent from the medical device.
  • effective amounts of bioactive agent can be released from the medical device.
  • the thinned lipid coating composition may to some extent absorb or adsorb into or onto the tissue.
  • the thinned lipid coating composition includes bioactive agent, which also absorbs into or adsorbs onto the tissue.
  • the thinned lipid coating composition may adhere to the tissue.
  • the thinned lipid coating composition can adhere bioactive agent to the tissue.
  • the decrease in thickness upon expanding effectively removes the lipid coating composition from the expandable and collapsible structure.
  • release of effective amounts of the bioactive agent from the medical device takes place in seconds to minutes, for example, 5 seconds to 2 minutes or 10 seconds to 1 minute.
  • the present lipid composition can include a lipid or mixture of lipids.
  • the lipid or mixture of lipids can, for example, be solid (e.g., waxy or paste-like) or semi-solid at room temperature and soft or liquid at the body temperature of a subject.
  • the lipid composition includes a lipid with a melting point at or above 40 °C and a lipid with a melting point at or below 20 °C. In an embodiment, the lipid composition includes a lipid with a melting point at or above 37 °C and a lipid with a melting point at or below 30 °C. In an embodiment, the lipid composition includes a lipid with a melting point of about 35 to about 45 °C and a lipid with a melting point of about 0 to about 35 °C.
  • Lipids that can be employed in the present lipid coating include: a marine oil, such as an oil from herring, menhaden, pilchard, sardine, whale, or a mixture thereof; soybean oil, cottonseed oil, corn oil, peanut oil, sunflower oil, safflower oil, olive oil, palm oil, or a mixture thereof; or mixtures thereof.
  • the lipid composition can be a mixture of a lipid that is liquid at room temperature and a lipid that is solid at room temperature.
  • a lipid that is liquid at room temperature is sold under the trade name High Oleic CV-65 canola oil (Cargill Inc., Minnetonka, MN).
  • the oils that are liquid at room temperature are not hydrogenated (e.g., neither partially hydrogenated nor fully hydrogenated).
  • the lipid that is solid at room temperature is an oil listed above that is partially or fully hydrogenated, for example, fully hydrogenated.
  • a lipid that is liquid at room temperature is sold under the trade name STABLE FLAKE C ® and is a cottonseed stearine product (C. & T. Refinery, Inc. of Richmond, Va.)
  • the lipid composition can include: an oil such as vegetable oil, flower oil, animal oil, marine oil (e.g., fish oil), tropical oil (e.g., coconut oil or palm oil), olive oil, peanut oil; lard, butterfat; a saturated fatty acid, for example, butanoic acid, hexanoic acid, octanoic acid, decanoic acid, dodecanoic acid, tetradecanoic acid, hexadecanoic acid, octadecanoic acid, or a mixture thereof; an unsaturated fatty acid, for example, octadecatrienoic acid, eicosanoic acid, eicosenoic acid, eicosatetraenoic acid, eicosapentaenoic acid, docosahexaenoic acid, palmitoleic acid, stearic acid, oleic acid, vaccenic acid, linoleic acid,
  • an oil
  • the present lipid composition can include one or more of a fat, a wax, a sterol, a phospholipid; a mono-, di-, or tri-glyceride; a fatty acyl, a glycerolipid, a glycerophospholipid, a sphingolipid (e.g., sphingomyelin), a saccharolipid, a polyketide, a sterol lipid, a prenol lipid, or a mixture thereof.
  • a fat a wax, a sterol, a phospholipid
  • a mono-, di-, or tri-glyceride e.g., a glycerolipid, a glycerophospholipid, a sphingolipid (e.g., sphingomyelin), a saccharolipid, a polyketide, a sterol lipid, a prenol lipid, or a mixture thereof.
  • Additional suitable lipids include a ceramide, a phosphosphingolipid, a glycosphingolipid, which can include fatty acid moieties that are saturated or mono- unsaturated with chain lengths from 16 to 26 carbon atoms.
  • the melting point of the present lipid composition can be determined by any one of a variety of art accepted methods. Suitable methods include the Mettler drop point test (see, e.g., ASTM D 3954). Briefly, in this test the sample to be measured is placed in a cup and heated at a given rate. The temperature at which a drop of molten material passes through a standard orifice is recorded. Other methods include the AOCS Method Cc 2-38 (the Wiley melting point), open capillary slip point, and the softening point tests.
  • lipid compositions of that are or appear solid at room temperature and components of these compositions include those described in U.S. Patent No. 6,544,579, which is incorporated herein by reference.
  • the lipid composition can be cooled at ambient temperature or supercooled to provide the lipid coating.
  • the lipid composition consists essentially of one or more lipids. In an embodiment, the lipid composition consists of one or more lipids. The lipid is generally not an active agent.
  • the present lipid composition can include one or more fatty acids, meaning free fatty acid not esterified or otherwise derivatized fatty acid.
  • the fatty acid can include or be a salt of the carboxylic acid (e.g., a salt of the fatty acid).
  • Suitable fatty acids include saturated and unsaturated fatty acids.
  • Suitable unsaturated fatty acids include mono-unsaturated fatty acids and polyunsaturated fatty acids.
  • the fatty acid composition includes a mono-unsaturated fatty acid.
  • the fatty acid composition includes a saturated fatty acid.
  • the fatty acid composition includes a saturated fatty acid and a mono- unsaturated fatty acid.
  • Suitable saturated fatty acids include those including 6 to 28 carbon atoms.
  • the saturated fatty acid is of the formula CH 3 (CH 2 ) n COOH, where 4 ⁇ n ⁇ 18.
  • n is 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18.
  • n is 10.
  • Suitable unsaturated fatty acids include those including 8 to 24 carbon atoms.
  • the unsaturated fatty acid is of the formula
  • m and o are independently greater than or equal to 2 and less than or equal to 18.
  • m is 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18.
  • o is 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18.
  • m is 7, o is 11 and the double bond is cis.
  • the unsaturated fatty acid can be described by C:D where
  • C is the number of carbon atoms and D is the number of double bonds.
  • C can be 6 to 24 and D can be 2 to 6.
  • C and D are integers.
  • D can be 1 and C can be 6 to 24.
  • the locations and stereochemistry of the double bond can be specified also.
  • the fatty acid composition includes a saturated fatty acid with a melting point at or above 30 °C and an unsaturated fatty acid with a melting point at or below 20 °C. In an embodiment, the fatty acid composition includes a saturated fatty acid with a melting point at or above 35 °C and an unsaturated fatty acid with a melting point at or below 35 °C. In an embodiment, the fatty acid composition includes a saturated fatty acid with a melting point of about 30 to about 45 °C and an unsaturated fatty acid with a melting point of about 0 to about 35 °C.
  • the lipid coating includes or is made of a plurality of fatty acids.
  • the plurality of fatty acids can be two fatty acids.
  • the lipid coating can be a fatty acid or mixture of (e.g. two) fatty acids.
  • the fatty acid or fatty acids can be a composition that is or that makes up the barrier layer.
  • the plurality of fatty acids can be a mixture of fatty acids that are solid at room temperature and soft or liquid at body temperature of the subject.
  • the plurality of fatty acids can be a mixture of fatty acids having a softening temperature greater than room temperature and less than body temperature of the subject.
  • the plurality of fatty acids can be a mixture of fatty acids having a melting point greater than room temperature and less than body temperature of the subject.
  • the present invention relates to a balloon catheter.
  • the balloon catheter includes a balloon.
  • This catheter includes an agent coating on the balloon, and the agent coating includes a bioactive agent.
  • This catheter includes a lipid coating on the agent coating, and the lipid coating includes a fatty acid.
  • This balloon catheter is effective for delivering the bioactive agent to a site within a subject.
  • the lipid composition includes a phospholipid.
  • Suitable phospholipids include, for example, a phosphatidic acid, a phosphatidylcholine, a phosphatidylethanolamine, a phosphatidylserine, or mixture thereof.
  • Suitable phosphatidylcholines include, for example: 1 ,2-Didecanoyl-5o- glycero-3-phosphocholine (CAS no. 3436-44-0), l,2-Dierucoyl-i «-gJycero-3- phosphocholine (CAS no. 56649-39-9), l,2-Dilinoleoyl-sn-glycero-3- phosphocholine (CAS no. 998-06-1), 1 ⁇ -Dilauroyl-sn-glycero-S -phosphocholine (CAS no. 18194-25-7), l,2-Dimyristoyl-sn-glycero-3-phosphocholine (CAS no.
  • lysophosphatidylcholine l-Myristoyl-2-palmitoyl-sn-glycero 3 -phosphocholine, 1- Myristoyl-2-stearoyl-£H-glycero-3-phosphocholine, l-Palmitoyl-2-myristoyl-sn- glycero-3-phosphocholine, 1 -Palmitoyl-2-oleoyl-5n-glycero-3 -phosphocholine (CAS no. 26853-31-6), 1 ,2-Distearoyl-5 «-glycero-3 -phosphocholine (CAS no.
  • Suitable lysophosphatidylcholines include, for example: 1-Myristoyl-sn- glycero-3 -phosphocholine (CAS no. 18194-24-6), l-Palmitoyl-_w-glycero-3- phosphocholine (CAS no. 17364-16-8), l-Stearoyl-sw-glycero-3-phosphocholine (CAS no. 19420-57-6), or mixture thereof.
  • Suitable phosphatidic acids include, for example: 1 ,2-Dierucoyl-sn-glycero- 3-phosphate (Sodium Salt) (CAS no. 80724-31-8), l,2-Dilauroyl- ⁇ n-glyeero-3- phosphate (Sodium Salt), 1 ,2-Dimyristoyl-_?n-glycero-3 -phosphate (Sodium Salt) (CAS no. 80724-3), 1 ,2-Dioleoyl-5H-glycero-3 -phosphate (Sodium Salt), 1,2- Dipalmitoyl-in-glycero-3-phosphate (Sodium Salt) (CAS no. 71065-87-7), 1,2- Distearoyl-sH-glycero-3-phosphate (Sodium Salt) (CAS no. 108321-18-2), or mixture thereof.
  • Suitable phosphatidylethanolamines include, for example: 1 ,2-Dierucoyl-s «- glycero-3-phosphoethanolamine (CAS no. 988-07-2), l,2-Dilauroyl-5n-glycero-3- phosphoethanolarnine, 1 ,2-Dimyristoyl-sn-glycero-3-phosphoethanolamine (CAS no. 988-07-2), 1 ,2-Dioleoyl-sn-glycero-3-phosphoethanolamine, 1 ,2-Dipalmitoyl- s «-glycero-3-phosphoethanolamine (CAS no.
  • Suitable phosphatidylserines include, for example: 1 ,2-Dilauroyl-5 «- glycero-3-phosphoserine (Sodium Salt), l ⁇ -Dimyristoyl-sn-glycero-S- phosphoserine (Sodium Salt), l,2-Dipalmitoyl-sn-glycero-3-phosphoserine (Sodium Salt), l,2-Distearoyl-sra-glycero-3-phosphoserine (Sodium Salt), 1 ,2-Dioleoyl-sn- glycero-3-phosphoserine (Sodium Salt) (CAS no. 70614-14-1), or mixture thereof.
  • the present invention also includes a method for delivering a bioactive agent to a subject using the present device.
  • the present method can include providing the present medical device.
  • the method can also include inserting the medical device into a subject, and then expanding the expandable and collapsible structure in the subject. Upon or after expansion an effective amount of the bioactive agent is released to the subject's tissue.
  • Expanding the portion of the device brings the coating into contact with the subject's tissue.
  • Contacting the subject's tissue with the coated portion of the device can remove lipid coating from the device.
  • the softened or melted (e.g., liquid) lipid coating composition may to some extent absorb or adsorb into or onto the tissue.
  • the softened or melted lipid coating composition includes bioactive agent, which also absorbs into or adsorbs onto the tissue.
  • the softened or melted (e.g., liquid) lipid coating composition may adhere to the tissue.
  • the softened or melted lipid coating composition can adhere bioactive agent to the tissue.
  • the softened or melted lipid coating composition may be squeezed out of the decreasing space between the device and the tissue as the device expands. If the device rubs against a portion of the tissue near the delivery site, this may also remove softened or melted lipid coating composition from the device.
  • the present method delivers a bioactive agent to a site in a subject.
  • This embodiment can include providing the present medical device.
  • the device provided can include an expandable and collapsible structure and an agent coating on the expandable and collapsible structure.
  • the agent coating can include a bioactive agent.
  • the device can also include a lipid coating on the agent coating.
  • the lipid coating can include a fatty acid.
  • This method includes inserting the medical device into the subject.
  • This method also includes expanding the expandable and collapsible structure at the site in the subject to contact a tissue at the site with the agent coating and the bioactive agent and to release bioactive agent to the tissue.
  • This method can include releasing a portion of the agent coating at the site.
  • Balloon angioplasty can be carried out for the treatment of diseased arteries to reduce atherosclerotic stenosis or to recanalize occluded arteries.
  • obstructed intraluminal passages are reopened or dilated by inflation of the balloon at the occluded site.
  • balloon catheter including one or more of the present coatings is inserted percutaneously into a luminal passage of a patient, such as an artery, vein, or airway. Once inserted, the balloon is advanced to the desired treatment site, where the balloon is inflated to dilate the luminal passage.
  • the present medical device can include any of a variety of coatings including a bioactive agent. Numerous suitable coatings and polymers useful in such coatings are described herein. Certain embodiments suitable for release of bioactive agent from the expandable and collapsible structure can release effective amounts of the bioactive agent at the delivery site in seconds or minutes.
  • the bioactive agent can be in an amorphous form incorporated into the coating or polymer matrix of the coating.
  • the coating including the bioactive agent can be on one or more portions of the expandable and collapsible structure, for example, on one or more portions of an exterior surface.
  • the coating including the bioactive agent can cover the entire surface of the balloon portion of a balloon catheter. In that manner, when the balloon is expanded in situ, the bioactive agent can be transferred to the
  • the coating including the bioactive agent can cover less than the entire surface of the expandable and collapsible structure, such as in a non-contiguous pattern.
  • a "non-contiguous" coating refers to a coating material that does not cover the structure (e.g., the entire balloon surface), but rather formed at one or more portions of the surface.
  • Non-contiguous coating patterns facilitate delamination of a biodegradable coated material from the expandable and collapsible surface when it is expanded.
  • a non-contiguous biodegradable coating may experience little or no fracturing before it becomes delaminated from the surface.
  • a non-contiguous biodegradable coatings can have a pattern that is easy to fracture, which facilitates delamination. In terms of inflation pressure, noncontiguous biodegradable coatings may require less force for coating delamination.
  • Biodegradable coatings having a non-contiguous pattern can be formed directly on the expandable and collapsible surface of a balloon, or can be formed in association with another coated material, such as a flexible hydrogel layer.
  • Noncontiguous patterns such as dotted and striped patterns, can be formed using a spray coating apparatus.
  • the coating including the bioactive agent can be a flexible hydrogel matrix.
  • the flexible hydrogel matrix can be made from a biostable hydrophilic polymer.
  • the polymer can be covalently bonded to the expandable and collapsible structure, covalently bonded to other hydrophilic polymers in the matrix, or both.
  • the biostable hydrophilic polymer is bonded to the substrate surface via reacted photogroups.
  • the coating including the bioactive agent can include a water-soluble polymer, for example, a water-soluble polymer such as poly(vinylpyrolidone).
  • the coating includes a polymer that is covalently bonded to the surface of expandable and collapsible structure via reacted photogroups.
  • the coating can also be formed from a composition in which the water-soluble polymer is in macromer form.
  • At least a portion of the coating including the bioactive agent is capable of becoming delaminated upon expansion of the expandable and collapsible structure in the subject.
  • the delaminated biodegradable polymeric matrix with bioactive agent can, for example, adhere to the target tissue.
  • Degradation of the delaminated polymeric matrix and release of the bioactive agent can occur at the target site.
  • the biodegradable polymeric matrix can be used in association with the flexible hydrogel matrix.
  • the flexible hydrogel matrix can be the release coating.
  • the biodegradable polymeric matrix can include the bioactive agent.
  • the present medical device includes a release coating.
  • the release coating can be on the expandable and contractible structure and can promote release of the coating including the bioactive agent (the agent coating) from this structure at the delivery site.
  • the release coating can be between the agent coating and the expandable and collapsible structure.
  • the release coating can be configured to promote release of the agent coating at the site within the subject.
  • the release coating can swell and push against the drug containing coating. In an embodiment, it pushes against and fractures the drug containing coating.
  • the release coating includes or is made of a water swellable polymer that rapidly absorbs water. Upon exposure to blood, water wicks into the layer and reduces the adhesion between the release layer and the agent coating.
  • the present medical device includes an adhesion coating.
  • the adhesion coating can be on the expandable and contractible structure and can promote adhesion of the agent coating to the subject's tissue at the delivery site.
  • the adhesion coating can be on the agent coating.
  • adhesion components can be in the agent coating.
  • the adhesion coating can include a cationic moiety or an adhesion protein.
  • the adhesion protein can be or can include collagen, heparin, laminin, or mixture thereof.
  • the adhesion coating can provide adhesive material for binding to a lesion, such as a lesion in a blood vessel. Components of the lesion to which adhesion can occur include cells, collagen, cholesterol, lipoproteins, or calcifications.
  • the device can include a degradable coated layer present between the coating including the bioactive agent and the surface of the expandable and collapsible structure.
  • the degradable layer can be present as a base coat on the surface of the expandable and collapsible structure.
  • a coating composition is formed that includes one or more matrix-forming polymer and bioactive agent.
  • the coating material is chosen and used in a composition suitable for forming a matrix with the bioactive agent.
  • a hydrophilic polymer is used to prepare an aqueous composition that also includes the bioactive agent.
  • the bioactive agent can be water insoluble, meaning that it does not readily dissolve in water.
  • bioactive agent is not included in a coating composition having the one or more matrix-forming polymer.
  • the bioactive agent is used in a subsequent coating step where they become associated with the coated polymeric matrix.
  • a coating composition includes an amount and type of polymeric material that provides suitable physical properties (such as elasticity and bioactive agent retention).
  • the amount of polymeric material used to form the matrix in the composition is at a concentration in the range of about 5 mg/mL to about 50 mg/mL, about 10 mg/mL to about 40 mg/mL, or about 10 mg/mL to about 20 mg/mL.
  • the polymeric material is present in the coating composition at about 15 mg/mL.
  • the polymeric material can also include pendent photo-reactive or polymerizable groups that can be activated to form a crosslinked matrix of polymer.
  • the amount of polymer in the composition can also be chosen based on the level of derivatization with these groups.
  • hydrophilic polymers useful as polymeric materials for matrix formation is synthetic hydrophilic polymers.
  • Synthetic hydrophilic polymers that are biostable i.e., that show no appreciable degradation in vivo
  • any suitable monomer including acrylic monomers, vinyl monomers, ether monomers, or combinations of any one or more of these types of monomers.
  • Acrylic monomers include, for example, methacrylate, methyl methacrylate, hydroxyethyl methacrylate, hydroxyethyl acrylate, methacrylic acid, acrylic acid, glycerol acrylate, glycerol methacrylate, acrylamide, methacrylamide,
  • DMA dimethylacrylamide
  • Vinyl monomers include, for example, vinyl acetate, vinylpyrrolidone, vinyl alcohol, and derivatives of any of these.
  • Ether monomers include, for example, ethylene oxide, propylene oxide, butylene oxide, and derivatives of any of these.
  • polymers that can be formed from these monomers include poly(acrylamide), poly(methacrylamide), poly( vinylpyrrolidone), poly(acrylic acid), poly(ethylene glycol), poly(vinyl alcohol), and poly(HEMA).
  • hydrophilic copolymers include, for example, methyl vinyl ether/maleic anhydride copolymers and vinyl pyrrolidone/(meth)acrylamide copolymers. Mixtures of homopolymers and/or copolymers can be used.
  • acrylamide-based polymers such as poly(NN- dimethylacrylamide-co-aminopropylmethacrylamide) and poly(acrylamide-co-N,N- dimethylaminopropylmethacrylamide) are described in example 2 of U.S. Patent Pub. No. 2006/0030669 filed September 17, 2004 (Taton et al), the disclosure of which is incorporated herein by reference.
  • the hydrophilic polymer is a vinyl pyrrolidone polymer, or a vinyl pyrrolidone/(meth)acrylamide copolymer such as
  • a PVP copolymer can be a copolymer of vinylpyrrolidone and a monomer selected from the group of acrylamide monomers.
  • Exemplary acrylamide monomers include (meth)acrylamide and (meth)acrylamide derivatives, such as alkyl(meth)acrylamide, as exemplified by dimethylacrylamide, and aminoalkyl(meth)acrylamide, as exemplified by aminopropylmethacrylamide and dimethylaminopropylmethacrylamide.
  • poly(vinylpyrrolidone-co-NN-dimethylaminopropylmethacrylamide) is described in example 2 of U.S. Patent Pub. No. 2006/0030669 (Taton et al).
  • the polymers and copolymers as described are derivatized with one or more photoactivatable group(s).
  • exemplary photoreactive groups that can be pendent from biostable hydrophilic polymer include aryl ketones, such as acetophenone, benzophenone, anthraquinone, anthrone, quinone, and anthrone-like heterocycles.
  • This provides a hydrophilic polymer having a pendent activatable photogroup that can be applied to the expandable and collapsible structure, and then treated with actinic radiation sufficient to activate the T/US2011/042553 photogroups and cause covalent bonding to a target, such as the material of the expandable and collapsible structure.
  • Use of photo-hydrophilic polymers can be used to provide a durable coating of a flexible hydrogel matrix, with the hydrophilic polymeric materials covalently bonded to the material of the expandable and collapsible structure.
  • a hydrophilic polymer having pendent photoreactive groups can be used to prepare the flexible hydrogel coating.
  • Methods of preparing hydrophilic polymers having photoreactive groups are known in the art. For example, methods for the preparation of photo-PVP are described in U.S. Patent No. 5,414,075, the disclosure of which is incorporated herein by reference. Methods for the preparation of photo- polyacrylamide are described in U.S. Patent No. 6,007,833, the disclosure of which is incorporated herein by reference. *
  • the polymers and copolymers as described are derivatized with one or more polymerizable group(s).
  • Polymers with pendent polymerizable groups are commonly referred to macromers.
  • the polymerizable group(s) can be present at the terminal portions (ends) of the polymeric strand or can be present along the length of the polymer. In one embodiment polymerizable groups are located randomly along the length of the polymer. Polymerizable groups can be activated form a crosslinked matrix in which the bioactive agent is immobilized.
  • Suitable crosslinking agents include two or more activatable groups, which can react with the polymers in the composition.
  • Suitable activatable groups include photoreactive groups as described herein, like aryl ketones, such as acetophenone, benzophenone, anthraquinone, anthrone, quinone, and anthrone-like heterocycles.
  • the photoactivatable cross-linking agent can be ionic, and can have good solubility in an aqueous composition. Thus, in some embodiments, at least one ionic photoactivatable cross-linking agent is used to form the coating.
  • the ionic cross- linking agent can include an acidic group or salt thereof, such as selected from sulfonic acids, carboxylic acids, phosphonic acids, salts thereof, and the like. 42553
  • Exemplary counter ions include alkali, alkaline earths metals, ammonium, protonated amines, and the like.
  • Exemplary ionic photoactivatable cross-linking agents include 4,5-bis(4- benzoylphenylmethyleneoxy) benzene- 1, 3 -disulfonic acid or salt; 2,5-bis(4- benzoylphenylmethyleneoxy)benzene-l ,4-disulfonic acid or salt; 2,5-bis(4- benzoylmethyleneoxy)benzene-l -sulfonic acid or salt; N,N-bis[2-(4- benzoylbenzyloxy)ethyl]-2-aminoethanesulfonic acid or salt, and the like. See U.S.
  • Natural polymers can also be used to form the matrix. Natural polymers include polysaccharides, for example, polydextrans, carboxymethylcellulose, and hydroxymethylcellulose; glycosaminoglycans, for example, hyaluronic acid;
  • polypeptides for example, soluble proteins such as collagen, albumin, and avidin; and combinations of these natural polymers. Combinations of natural and synthetic polymers can also be used.
  • Selection of the first and second polymers can also be based on other properties of the polymers such as molecular weight, solubility, and rheology.
  • the polymer matrix includes an amphiphilic copolymer, a low molecular weight hydrophobic polymer, an organogel, a deformable hydrogel, a plurality thereof, or a mixture thereof.
  • the coating including a bioactive agent includes or is made of an amphiphilic copolymer. Suitable amphiphilic copolymers include a
  • lactide/glycolide/caprolatone/polyethylene glycol copolymer Such a copolymer can include blocks of polyethylene glycol.
  • an amphiphilic copolymer includes hydrophobic domains that enhance solubility of hydrophobic drugs and hydrophilic domains absorb water allowing the coating to swell upon exposure to blood.
  • the coating including a bioactive agent includes or is made of a hydrophobic polymer of low average molecular weight.
  • Suitable low molecular weight hydrophobic polymers include a
  • the agent coating includes one or more solvents and the bioactive agent.
  • the agent coating includes an organogel.
  • the agent coating includes a deformable hydrogel.
  • the agent coating includes a lipid.
  • the lipid can enhance adhesion and penetration of drug into tissue.
  • Drug can be emulsified into a lipid carrier.
  • the drug is dissolved or dispersed in a deformable polymer layer, e.g., a hydrophobic polymer, an organogel, or a deformable hydrogel.
  • a deformable polymer layer e.g., a hydrophobic polymer, an organogel, or a deformable hydrogel.
  • such a coating can flow or escape from the balloon surface and conform or adhere to the tissue upon expansion of the balloon.
  • the biodegradable polymer can include one or more (e.g., 1, 2, 3 or 4) specific biodegradable polymers, for use in forming an implant in vivo. Suitable polymers will be biodegradable and will be substantially soluble in the
  • the biodegradable polymer can have a solubility of at least about 50 g/L in the biocompatible solvent system, at 25 °C and 1 atm.
  • the biodegradable polymer will not include a polymer that is substantially insoluble in the biocompatible solvent system.
  • the biodegradable polymer will not include a biodegradable polymer that is substantially insoluble in water or bodily fluids.
  • Suitable specific classes of polymers include, e.g., polylactides,
  • polyglycolides polycaprolactones, polyanhydrides, polyamines, polyurethanes, polyesteramides, polyorthoesters, polydioxanones, polyacetals, polyketals, polycarbonates, polyorthocarbonates, polyphosphazenes, succinates, poly(malic acid), poly(amino acids), polyvinylpyrrolidone, polyethylene glycol,
  • polyhydroxycellulose polysaccharides, chitin, chitosan, and copolymers, block copolymers, multi-block co-polymers, multi-block co-polymers with polyethylene glycol (PEG), polyols, terpolymers and mixtures thereof.
  • PEG polyethylene glycol
  • the biodegradable polymer has a viscosity of at least about 100 cP at 37°C. In other embodiments, the biodegradable polymer has a viscosity of about 1,000 cP to about 30,000 cp at 37°C, about 5,000 cP to about 25,000 cp at 37°C, or about 10,000 cP to about 20,000 cp at 37°C.
  • the biodegradable polymer is hydrophobic.
  • the biodegradable polymer includes a block copolymer.
  • the biodegradable polymer is a polyethylene glycol (PEG) containing tri-block co-polymer.
  • the polymer contains functional side groups.
  • the biodegradable polymer can be present in any suitable and effective amount, provided the biodegradable polymer is substantially soluble in the solvent system, and in combination with the solvent system will form an implant in vivo.
  • the biodegradable polymer is present in about 10 wt.% to about 40 wt.% of the formulation. In an embodiment, the biodegradable polymer is present in about 40 wt.% to about 90 wt.% of the formulation.
  • the biodegradable polymer can include a poly(ether ester) multi-block copolymer, for example, that sold under the trade name
  • the biodegradable polymer can include a polyglycerol fatty acid ester.
  • the biodegradable polymer can include a PEG-PBT polymer.
  • the biodegradable polymer can include a poly(ester-amide) polymer (PEA).
  • One suitable class of biodegradable polymers useful in the present invention includes the poly(ether ester) multi-block copolymers. These multi-block copolymers are composed of various pre-polymer building blocks of different combinations of DL-lactide, glycolide, e-caprolactone and polyethylene glycol. By varying the molecular composition, molecular weight (Mw 1200 - 6000) and ratio of the pre-polymer blocks, different functionalities can be introduced into the final polymer, which enables the creation of polymers with various physio-chemical 42553 properties. Both hydrophobic as well as hydrophilic/swellable polymers and slowly degrading as well as rapidly degrading polymers can be designed.
  • the poly(ether ester) multi-block copolymers can include a polymer as shown below (formula III):
  • n and p are each independently glycolide
  • n polyethylene glycol, Mw 300-1000;
  • o is e-caprolactone
  • poly(ether ester) multi-block copolymers can degrade completely via hydrolysis into non-toxic degradation products which are metabolized and/or excreted through the urinary pathway.
  • the multi-block copolymers can specifically include two hydrolysable segments having a different composition, linked by a multifunctional, specifically an aliphatic chain-extender, and which are specifically essentially completely amorphous under physiological conditions (moist environment, body temperature, which is approximately 37°C for humans).
  • Ri and R 2 can be amorphous polyester, amorphous poly ether ester or amorphous polycarbonate; or an amorphous pre-polymer that is obtained from combined ester, ether and/or carbonate groups.
  • Ri and R 2 can contain polyether groups, which can result from the use of these compounds as a polymerization initiator, the polyether being amorphous or crystalline at room temperature.
  • Rj and R 2 are derived from amorphous pre-polymers or blocks A and B, respectively, and R and R 2 are not the same.
  • R] and R 2 can contain a polyether group at the same time. In a specific embodiment, only one of them will contain a polyether group;
  • z is zero or a positive integer
  • x and y are both positive integers, which can both specifically be at least 1 , whereas the sum of x and y (x+y) can specifically be at most 1000, more specifically at most 500, or at most 100.
  • Q1-Q6 are linking units obtained by the reaction of the pre-polymers with the multifunctional chain-extender.
  • Q1-Q6 are independently amine, urethane, amide, carbonate, ester or anhydride. The event that all linking groups Q are different being rare and not preferred.
  • one type of chain-extender can be used with three pre-polymers having the same end-groups, resulting in a copolymer of formula (1) with six similar linking groups.
  • pre-polymers Rj and R 2 are differently terminated, two types of groups Q will be present: e.g. Ql and Q2 will be the same between two linked pre-polymer segments Ri, but Ql and Q2 are different when Ri and R 2 are linked.
  • the groups Ql and Q2 are the same when two pre-polymers are present that are both terminated with the same end- group (which is usually hydroxyl) but are different when the pre-polymers are differently terminated (e.g. PEG which is diol terminated and a di-acid terminated 'tri-block' pre-polymer).
  • the outer segments should be essentially free of PEG, because the coupling reaction by ring opening can otherwise not be carried out successfully. Only the inner block can be initiated by a PEG molecule.
  • the a/b ratio (corresponding to x/y in formula (1)) may be unity or away from unity.
  • the pre-polymers can be mixed in any desired amount and can be coupled by a multifunctional chain extender, viz.
  • Those according to formula (2) or (3) have a structure (aba)n and (bab)n wherein the aba and bab 'triblock' pre-polymers are chain-extended with a di-functional molecule.
  • the method to obtain a copolymer with a random distribution of a and b (and optionally c) is far more advantageous than when the segments are alternating in the copolymer such as in (ab)n with the ratio of pre-polymers a and b being 1.
  • the composition of the copolymer can then only be determined by adjusting the pre- polymer lengths.
  • the a and b segment lengths in (ab)n alternating copolymers are smaller than blocks in block-copolymers with structures ABA or AB.
  • the pre-polymers of which the a and b (and optionally c) segments are formed in (ab)r, (abc)r, (ab)n and (abc)n are linked by the di-functional chain- extender.
  • This chain-extender can specifically be a diisocyanate chain-extender, but can also be a diacid or diol compound.
  • the linking units will be urethane groups.
  • the linking units are amide groups.
  • randomly segmented copolymers refers to copolymers that have a random distribution (i.e. not alternating) of the segments a and b: (ab)r or a, b and c: (abc)r.
  • One suitable class of biodegradable polymers useful in the present invention includes the polyesteramide polymers having a subunit of the formula (V):
  • x is C 2 -C 12 ,
  • y is C-2-C12
  • R is -CH(CH 3 ) 2 , -CH 2 CH(CH 3 ) 2 , -CH(CH 3 )CH 2 CH 3 , - CH 2 (CH 2 ) 2 CH 3 , - CH 2 C 6 Hs,
  • the C 2 -C 12 can be (C 2 -C 12 ) alkyl. In other specific embodiments, the C 2 -C 12 can be (C 2 -C 12 ) alkyl, optionally substituted.
  • Such polymers are described, for example, in U.S. Patent No. 6,703,040.
  • Polymers of this nature can be described with a nomenclature of x-aa-y, wherein "x" represents an alkyl diol with x carbon atoms, "aa” represents an amino acid such as leucine or phenylalanine, and y represents an alkyldicarboxylic acid with y carbon atoms, and wherein the polymer is a polymerization of the diol, the dicarboxylic acid, and the amino acid.
  • An exemplary polymer of this type is 4-Leu- .
  • One suitable class of biodegradable polymers useful in the present invention includes the poly(ester-amide) polymers.
  • Such polymers can be prepared by polymerization of a diol, a dicarboxylic acid and an alpha-amino acid through ester and amide links in the form (DACA) n .
  • An example of a (DACA) n polymer is shown below in formula VI.
  • Suitable amino acids include any natural or synthetic alpha- amino acid, specifically neutral amino acids.
  • Diols can be any aliphatic diol, including alkylene diols like HO-(CH 2 ) k -OH (i.e. non-branched), branched diols (e.g., propylene glycol), cyclic diols (e.g.
  • Aromatic diols e.g., bis-phenols are less useful for these purposes since they are more toxic, and polymers based on them have rigid chains that are less likely to biodegrade.
  • k is 2-12 (e.g., 2, 3, 4, or 6);
  • R is -CH(CH 3 ) 2 , -CH 2 CH(CH 3 ) 2 , -CH(CH 3 )CH 2 CH 3 , - CH 2 (CH 2 ) 2 CH 3 , - CH 2 (C 6 H 5 ), or
  • A is L-phenylalanine (Phe-PEA) and A is L- leucine (Leu-PEA).
  • Phe-PEA Phe-PEA
  • Leu-PEA L- leucine
  • the ratio of Phe-PEA to Leu-PEA is from 10:1 to 1:1. In other specific embodiments, the ratio of Phe-PEA to Leu-PEA is from 5:1 to 2.5:1.
  • biodegradable polysaccharide for example, maltodextrin is a natural biodegradable polysaccharide that is processed from starch.
  • exemplary natural biodegradable polysaccharides include maltodextrin, amylose, cyclodextrin, polyalditol, hyaluronic acid, dextran, heparin, chondroitin sulfate, dermatan sulfate, heparan sulfate, keratan sulfate, dextran, dextran sulfate, pentosan polysulfate, and chitosan.
  • polysaccharides are low molecular weight polymers that have little or no branching, such as those that are derived from and/or found in starch preparations, for example, maltodextrin, amylose, and cyclodextrin. Therefore, the natural biodegradable polysaccharide can be a substantially non-branched or completely non-branched poly(glucopyranose) polymer.
  • Amylose or "amylose polymer” refers to a linear polymer having repeating glucopyranose units that are joined by af-1,4 linkages. Some amylose polymers can have a very small amount of branching via ct-l,6 linkages (about less than 0.5% of the linkages) but still demonstrate the same physical properties as linear
  • amylose polymers do.
  • amylose polymers derived from plant sources have molecular weights of about lxlO 6 Da or less.
  • Amylopectin comparatively, is a branched polymer having repeating glucopyranose units that are joined by of-1,4 linkages to form linear portions and the linear portions are linked together via o-l ,6 linkages.
  • the branch point linkages are generally greater than 1% of the total linkages and typically 4%-5% of the total linkages.
  • amylopectin derived from plant sources have molecular weights of lxl 0 7 Da or greater.
  • starch preparations having a high amylose content, purified amylose, synthetically prepared amylose, or enriched amylose preparations can be used in the preparation of a hydrophobic derivative of amylose.
  • amylose is typically present along with amylopectin, which is a branched polysaccharide. If a mixture of amylose and a higher molecular weight precursor is used (such as amylopectin), amylose can be present in the composition in an amount greater than the higher molecular weight precursor.
  • starch preparations having high amylose content, purified amylose, synthetically prepared amylose, or enriched amylose preparations can be used in the preparation of a hydrophobic derivative of amylose polymer.
  • the composition includes a mixture of polysaccharides including amylose wherein the amylose content in the mixture of polysaccharides is 50% or greater, 60% or greater, 70% or greater, 80% or greater, or 85% or greater by weight.
  • the composition includes a mixture of polysaccharides including amylose and amylopectin and wherein the amylopectin content in the mixture of polysaccharides is 30% or less, or 15% or less.
  • the amount of amylopectin present in a starch may also be reduced by treating the starch with amylopectinase, which cleaves a-l ,6 linkages resulting in the debranching of amylopectin into amylose.
  • Steps may be performed before, during, and/or after the process of derivatizing the amylose polymer with a pendent group comprising a hydrocarbon segment to enrich the amount of amylose, or purify the amylose.
  • Amylose of particular molecular weights can be obtained commercially or can be prepared.
  • 70 kDa, 110 kDa, and 320 kDa can be obtained from Nakano Vinegar Co., Ltd.
  • amylose of a particular size range may depend on factors such as the physical characteristics of the composition (e.g., viscosity), the desired rate of degradation of the implant, and the nature and amount of the active pharmaceutical ingredient (API).
  • Purified or enriched amylose preparations can be obtained commercially or can be prepared using standard biochemical techniques such as chromatography.
  • high-amylose cornstarch can be used to prepare the hydrophobic derivative.
  • Maltodextrin is typically generated by hydrolyzing a starch slurry with heat- stable a-amylase at temperatures at 85-90 °C until the desired degree of hydrolysis is reached and then inactivating the a-amylase by a second heat treatment.
  • the maltodextrin can be purified by filtration and then spray dried to a final product.
  • DE dextrose equivalent
  • maltodextrins are considered to have molecular weights that are less than amylose molecules.
  • a starch preparation that has been totally hydrolyzed to dextrose (glucose) has a DE of 100, whereas starch has a DE of about zero.
  • a DE of greater than 0 but less than 100 characterizes the mean-average molecular weight of a starch hydrolysate, and maltodextrins are considered to have a DE of less than 20.
  • Maltodextrins of various molecular weights for example, in the range of about 500 Da to 5000 Da are commercially available (for example, from CarboMer, San Diego, Calif).
  • Another contemplated class of natural biodegradable polysaccharides is natural biodegradable non-reducing polysaccharides.
  • a non-reducing polysaccharides is natural biodegradable non-reducing polysaccharides.
  • polysaccharide can provide an inert matrix thereby improving the stability of active pharmaceutical ingredients (APIs), such as proteins and enzymes.
  • APIs active pharmaceutical ingredients
  • a non-reducing polysaccharide refers to a polymer of non-reducing disaccharides (two
  • trehalose a-D- glucopyranosyl o-D-glucopyranoside
  • sucrose ⁇ -D-fractofuranosyl a-D- glucopyranoside
  • An exemplary non-reducing polysaccharide includes polyalditol which is available from GPC (Muscatine, Iowa).
  • Dextran is an a-D-l,6-glucose-linked glucan with side-chains 1-3 linked to the backbone units of the dextran biopolymer. Dextran includes hydroxyl groups at the 2, 3, and 4 positions on the glucopyranose monomelic units. Dextran can be obtained from fermentation of sucrose-containing media by Leuconostoc mesenteroides B512F.
  • Chondroitin sulfate includes the repeating disaccharide units of D- galactosamine and D-glucuronic acid, and typically contains between 15 to 150 of these repeating units. Chondroitinase AC cleaves chondroitin sulfates A and C, and chondroitin.
  • the polysaccharide portion and the hydrophobic portion include the predominant portion of the hydrophobic derivative of the natural biodegradable polysaccharide. Based on a weight percentage, the polysaccharide portion can be about 25% wt of the hydrophobic derivative or greater, in the range of about 25% to about 75%, in the range of about 30% to about 70%, in the range of about 35% to about 65%, in the range of about 40% to about 60%, or in the range of about 45% to about 55%.
  • the hydrophobic derivative has the properties of being insoluble in water.
  • a hydrophobic derivative can be prepared by associating one or more hydrophobic compound(s) with a natural biodegradable polysaccharide polymer. Methods for preparing hydrophobic derivatives of natural biodegradable
  • polysaccharides are described herein.
  • the hydrophobic derivatives of the natural biodegradable polysaccharides specifically have an average molecular weight of up to about 1,000,000 Da, up to about 300,000 Da or up to about 100,000 Da. Use of these molecular weight derivatives can provide implants with desirable physical and drug-releasing properties. In some aspects the hydrophobic derivatives have a molecular weight of about 250,000 Da or less, about 100,000 Da or less, about 50,000 Da or less, or 25,000 Da or less. Particularly specific size ranges for the natural biodegradable polysaccharides are in the range of about 2,000 Da to about 20,000 Da, or about 4,000 Da to about 10,000 Da.
  • hydrophobic portion will generally cause an increase in molecular weight of the polysaccharide from its underivatized, starting molecular weight.
  • the amount increase in molecular weight can depend on one or more factors, including the type of polysaccharide derivatized, the level of derivation, and, for example, the type or types of groups attached to the polysaccharide to provide the hydrophobic portion.
  • the addition of hydrophobic portion causes an increase in molecular weight of the polysaccharide of about 20% or greater, about 50% or greater, about 75% or greater, about 100%) or greater, or about 125%, the increase in relation to the underivatized form of the polysaccharide.
  • a maltodextrin having a starting weight of about 3000 Da is derivatized to provide pendent hexanoate groups that are coupled to the
  • polysaccharide that includes the unit of formula (I) above can be a compound of formula (II):
  • each M is independently a monosaccharide unit
  • each L is independently a suitable linking group, or is a direct bond
  • each PG is independently a pendent group
  • each x is independently 0 to about 3, such that when x is 0, the bond between L and M is absent
  • y is about 3 to about 5,000
  • Each R 1 is independently hydrogen, alkyl, cycloalkyl, cycloalkyl alkyl, aryl, aryl alkyl, heterocyclyl or heteroaryl, each alkyl, cycloalkyl, aryl, heterocycle and heteroaryl is optionally substituted, and each alkyl, cycloalkyl and heterocycle is optionally partially unsaturated.
  • the monosaccharide unit (M) can include D-glucopyranose (e.g., OHD-glucopyranose). Additionally, the D-glucopyranose (e.g., OHD-glucopyranose).
  • M monosaccharide unit (M) can include non-macrocyclic poly-o(l ⁇ 4)
  • the monosaccharide unit (M) can include glucopyranose units, wherein at least about 90% are linked by o l ⁇ 4) glycosidic bonds.
  • the monosaccharide unit (M) can include glucopyranose units, wherein at least about 90% are linked by o l ⁇ 6) glycosidic bonds.
  • each of the monosaccharides in the polysaccharide can be the same type (homopolysaccharide), or the monosaccharides in the polysaccharide can differ (heteropolysaccharide).
  • the polysaccharide can include up to about 5,000 monosaccharide units (i.e., y in the formula (I) or (II) is up to 5,000).
  • the monosaccharide units can be glucopyranose units (e.g., Of-D-glucopyranose units).
  • y in the formula (I) or (II) can specifically be about 3-5,000 or about 3-4,000 or about 100 to 4,000.
  • the polysaccharide is non-macrocyclic. In other specific embodiments, the polysaccharide is linear. In other specific embodiments, the polysaccharide is branched. In yet further specific embodiments, the
  • polysaccharide is a natural polysaccharide (PS).
  • the polysaccharide will have a suitable glass transition temperature (Tg). In one embodiment, the polysaccharide will have a glass transition temperature (Tg) of at least about 35°C (e.g., about 40°C to about 150°C). In an embodiment, the polysaccharide will have a glass transition temperature (Tg) of-30°C to about 0°C.
  • Tg glass transition temperature
  • a "pendant group” refers to a group of covalently bonded carbon atoms having the formula (CH n ) m , wherein m is 2 or greater, and n is independently 2 or 1.
  • the monomelic units of the hydrophobic polysaccharides described herein typically include monomeric units having ring structures with one or more reactive groups. These reactive groups are exemplified by hydroxyl groups, such as the ones that are present on glucopyranose-based monomeric units, e.g., of amylose and maltodextrin. These hydroxyl groups can be reacted with a compound that includes a hydrocarbon segment and a group that is reactive with the hydroxyl group (a hydroxyl-reactive group).
  • hydroxyl reactive groups include acetal, carboxyl, anhydride, acid halide, and the like. These groups can be used to form a hydrolytically cleavable covalent bond between the hydrocarbon segment and the polysaccharide backbone.
  • the method can provide a pendent group having a hydrocarbon segment, the pendent group linked to the polysaccharide backbone with a cleavable ester bond.
  • the synthesized hydrophobic derivative of the natural biodegradable polysaccharide can include chemical linkages that are both enzymatically cleavable (the polymer backbone) and non-enzymatically
  • the hydroxyl reactive groups include those such as isocyanate and epoxy. These groups can be used to form a non-cleavable covalent bond between the pendent group and the polysaccharide backbone.
  • the 2553 synthesized hydrophobic derivative of the natural biodegradable polysaccharide includes chemical linkages that are enzymatically cleavable.
  • reactive groups such as carboxyl groups, acetyl groups, or sulphate groups, are present on the ring structure of monomeric units of other natural biodegradable polysaccharides, such as chondrotin or hyaluronic acid. These groups can also be targeted for reaction with a compound having a hydrocarbon segment to be bonded to the polysaccharide backbone.
  • the hydrophobic derivative of the natural biodegradable polysaccharide Various factors can be taken into consideration in the synthesis of the hydrophobic derivative of the natural biodegradable polysaccharide. These factors include the physical and chemical properties of the natural biodegradable polysaccharide, including its size, and the number and presence of reactive groups on the polysaccharide and solubility, the physical and chemical properties of the compound that includes the hydrocarbon segment, including its the size and solubility, and the reactivity of the compound with the polysaccharide.
  • any suitable synthesis procedure can be performed. Synthesis can be carried out to provide a desired number of groups with hydrocarbon segments pendent from the polysaccharide backbone. The number and/or density of the pendent groups can be controlled, for example, by controlling the relative concentration of the compound that includes the hydrocarbon segment to the available reactive groups (e.g., hydroxyl groups) on the polysaccharide.
  • the type and amount of groups having the hydrocarbon segment pendent from the polysaccharide is sufficient for the hydrophobic polysaccharide to be insoluble in water.
  • a hydrophobic polysaccharide is obtained or prepared wherein the groups having the hydrocarbon segment pendent from the polysaccharide backbone in an amount in the range of 0.25 (pendent group): 1 (polysaccharide monomer) by weight.
  • the weight ratio of glucopyranose units to pendent groups can vary, but will typically be about 1 :1 to about 100:1. Specifically, the weight ratio of
  • glucopyranose units to pendent groups can be about 1 : 1 to about 75: 1 , or about 1 : 1 to about 50: 1. Additionally, the nature and amount of the pendent group can provide a suitable degree of substitution to the polysaccharide. Typically, the degree of substitution will be in the range of about 0.1-5 or about 0.5-2. To exemplify these levels of derivation, very low molecular weight (less than 10,000 Da) glucopyranose polymers are reacted with compounds having the hydrocarbon segment to provide low molecular weight hydrophobic glucopyranose polymers.
  • the natural biodegradable polysaccharide maltodextrin in an amount of 10 g is dissolved in a suitable solvent, such as tetrahydrofuran.
  • a solution having butyric anhydride in an amount of 18 g (0.11 mols) is added to the maltodextrin solution.
  • the reaction is allowed to proceed, effectively forming pendent butyrate groups on the pyranose rings of the maltodextrin polymer.
  • This level of derivation results in a degree of substitution (DS) of butyrate group of the hydroxyl groups on the maltodextrin of about 1.
  • maltodextrin-butyrate DS 1 For maltodextrin and other polysaccharides that include three hydroxyl groups per monomelic unit, on average, one of the three hydroxyl groups per glycopyranose monomelic unit becomes substituted with a butyrate group.
  • a maltodextrin polymer having this level of substitution is referred to herein as maltodextrin-butyrate DS 1.
  • the DS refers to the average number of reactive groups (including hydroxyl and other reactive groups) per monomelic unit that are substituted with pendent groups comprising hydrocarbon segments.
  • butyrylated maltodextrin having a DS of 2.5 is prepared by reacting 10 g of maltodextrin (MW 3000-5000 Da; ⁇ 3 mmols) with 0.32 mols butyric anhydride.
  • implants formed from hydrophobic derivatives having a substantial amount of groups having the hydrocarbon segments bonded to the polysaccharide backbone are generally more hydrophobic and can be more resistant to degradation.
  • an implant formed from maltodextrin-butyrate DS 1 has a rate of degradation that is faster than an implant formed from maltodextrin-butyrate DS2.
  • the implant is formed using a hydrophobic polysaccharide having pendent groups with hydrocarbon segments being short chain branched alkyl group.
  • Exemplary short chain branched alkyl group are branched C 4 -C 10 groups.
  • the preparation of a hydrophobic polymer with these types of pendent groups is exemplified by the reaction of maltodextrin with valproic acid/anhydride with maltodextrin (MD-val). The reaction can be carried out to provide a relatively lower degree of substitution of the hydroxyl groups, such as is in the range of 0.5- 1.5. Although these polysaccharides have a lower degree of substitution, the short chain branched alkyl group imparts considerable hydrophobic properties to the polysaccharide.
  • the MD-val forms coatings that are very compliant and durable. Because of the low degrees of substitution, the pendent groups with the branched C 8 segment can be hydrolyzed from the polysaccharide backbone at a relatively fast rate, thereby providing a biodegradable coatings that have a relatively fast rate of degradation.
  • hydrolysis and loss of groups pendent from the polysaccharide backbone This can alter the properties of the implant, and can result in greater access to enzymes that promote the degradation of the natural biodegradable polysaccharide.
  • Various synthetic schemes can be used for the preparation of a hydrophobic derivative of a natural biodegradable polysaccharide.
  • pendent polysaccharide hydroxyl groups are reacted with a compound that includes a hydrocarbon segment and a group that is reactive with the hydroxyl groups. This reaction can provide polysaccharide with pendent groups comprising hydrocarbon segments.
  • Any suitable chemical group can be coupled to the polysaccharide backbone and provide the polysaccharide with hydrophobic properties, wherein the
  • the pendent group can include one or more atoms selected from carbon (C), hydrogen (H), oxygen (O), nitrogen (N), and sulfur (S).
  • the compound having a hydrocarbon segment that is reacted with the polysaccharide backbone is derived from a natural compound.
  • Natural compounds with hydrocarbon segments include fatty acids, fats, oils, waxes, phospholipids, prostaglandins, thromboxanes, leukotrienes, terpenes, steroids, and lipid soluble vitamins.
  • Exemplary natural compounds with hydrocarbon segments include fatty acids and derivatives thereof, such as fatty acid anhydrides and fatty acid halides.
  • Exemplary fatty acids and anhydrides include acetic, propionic, butyric, isobutyric, valeric, caproic, caprylic, capric, and lauric acids and anhydrides, respectively.
  • the hydroxyl group of a polysaccharide can be reacted with a fatty acid or anhydride to bond the hydrocarbon segment of the compound to the polysaccharide via an ester group.
  • the hydroxyl group of a polysaccharide can also cause the ring opening of lactones to provide pendent open-chain hydroxy esters.
  • Exemplary lactones that can be reacted with the polysaccharide include caprolactone and glycolides.
  • the hydrophobic derivative of the natural biodegradable polysaccharide can also be synthesized having combinations of pendent groups with two or more different hydrocarbon segments, respectively.
  • the hydrophobic derivative can be synthesized using compounds having hydrocarbon segments with different alkyl chain lengths.
  • a polysaccharide is reacted with a mixture of two or more fatty acids (or derivatives thereof) selected from the group of acetic acid, propionic acid, butyric acid, isobutyric acid, valeric acid, caproic acid, caprylic acid, capric acid, and lauric acid to generate the hydrophobic derivative.
  • the hydrophobic derivative is synthesized having a non- hydrolyzable bond linking the hydrocarbon segment to the polysaccharide backbone.
  • Exemplary non-hydrolyzable bonds include urethane bonds.
  • the hydrophobic derivative of the natural biodegradable polysaccharide can also be synthesized so that hydrocarbon segments are individually linked to the polysaccharide backbone via both hydrolyzable and non-hydrolyzable bonds.
  • a hydrophobic derivative is prepared by reacting a mixture of butyric acid anhydride and butyl isocyanate with maltodextrin. This yields a hydrophobic derivative of maltodextrin with pendent butyric acid groups that are individually covalently bonded to the maltodextrin backbone with hydrolyzable ester linkages and non-hydrolyzable urethane linkages.
  • the degradation of a coating having this type of hydrophobic derivative can occur by loss of the butyrate groups from hydrolysis of the ester linkages. However, a portion of the butyrate groups (the ones that are bonded via the urethane groups) are not removed from the
  • the group that is pendent from the polysaccharide backbone has properties of an active pharmaceutical ingredient (API).
  • the implants include polysaccharide-coupled API.
  • an API which has a hydrocarbon segment can be hydrolyzed from the natural biodegradable polymer and released from the matrix to provide a therapeutic effect.
  • a therapeutically useful compound having a hydrocarbon segments is butyric acid, which has been shown to elicit tumor cell differentiation and apoptosis, and is thought to be useful for the treatment of cancer and other blood diseases.
  • hydrocarbon segments include valproic acid and retinoic acid. These compounds can be coupled to a
  • polysaccharide backbone to provide a pendent group, and then cleaved from the polysaccharide backbone upon degradation of the implant in vivo.
  • Retinoic acid is known to possess antiproliferative effects and is thought to be useful for treatment of proliferative vitreoretinopathy (PVR).
  • the pendent group that provides a therapeutic effect can also be a natural compound (such as butyric acid, valproic acid, and retinoic acid).
  • Another illustrative class of compounds that can be coupled to the polysaccharide backbone is the corticosteroids.
  • An exemplary corticosteroid is triamcinolone.
  • Triamcinolone hexanoic acid is prepared by reaction of triamcinolone with ketohexanoic acid; an acid chloride of the resulting triamcinolone hexanoic acid can be formed and then reacted with the natural biodegradable polymer, such as maltodextrin or polyalditol, resulting in pendent triamcinolone groups coupled via ester bonds to the natural biodegradable polymer.
  • the natural biodegradable polymer such as maltodextrin or polyalditol
  • the hydrophobic derivative of the natural biodegradable polysaccharide can also be synthesized having two or more different pendent groups, wherein at least one of the pendent groups includes an API.
  • the hydrophobic polysaccharide can be synthesized with an amount of a pendent groups including an API, that when released from the polysaccharide, provides a therapeutic effect to the subject.
  • An example of such a hydrophobic derivative is maltodextrin-caproate-triamcinolone.
  • This hydrophobic derivative can be prepared by reacting a mixture including triamcinolone hexanoic acid and an excess of caproic anhydride (n-hexanoic anhydride) with maltodextrin to provide a derivative with a DS of 2.5.
  • maltodextrin to provide pendent chemical group having a hydrocarbon segment that is a phenyl group, and a non-hydrocarbon segment that is an acetate group wherein the pendent group is linked to the polysaccharide via an ester bond.
  • biodegradable polymers that include the hydrophobic derivatives of natural biodegradable polysaccharides (referred to as EurekaTM SOLO polymers) can be found, for example, in U.S. Patent Publication Nos. 2007/0218102, 2007/0260054 and 2007/0224247, and references cited therein.
  • a biodegradable coating on an expandable and collapsible structure can be made by preparing a coating composition including a biodegradable multiblock copolymer, such containing glycolic acid, caprolactone, and PEG polymeric blocks, dissolved in acetone at 30 mg/mL and applied by spraying the solution onto the structure (e.g., a balloon) (with or without a hydrogel base coat).
  • Bioactive agent e.g., in bioactive agent form
  • paclitaxel dissolved in methanol, or present as bioactive agent in water
  • a coating composition including polymeric material and bioactive agent is prepared and then applied to the surface of the expandable and collapsible structure.
  • a coating composition is used including bioactive agent at a concentration in the range of about 10 mg/mL to about 50 mg/mL.
  • polymeric material can be applied to the surface independently of the bioactive agent.
  • a polymeric composition can be applied to the surface in a first step, and then in a second step a composition having bioactive agent (and without polymeric coating material) can be to the applied to the previously coated polymer.
  • a coating composition having bioactive agent at a concentration in the range of about 10 mg/mL to about 50 mg/mL (without polymeric coating material) is used. Additional, optional, steps can be performed to apply the same or other polymeric material, such as a topcoat, over the bioactive agent.
  • a coating is formed on the surface of the expandable and collapsible structure using a spray coating process.
  • a balloon catheter is mounted on an apparatus that can manipulate the balloon for coating using a spray deposition process.
  • a coating composition is dip-coated onto the surface of the expandable and collapsible structure to form a coated surface.
  • the composition is brushed onto the surface of the expandable and collapsible structure.
  • the substrate can be subject to more than one step of coating with a mixture of polymeric material and bioactive agent, thereby allowing the formation of multiple layers on the substrate surface.
  • the free radical polymerization of the polymerizable groups can be caused by the activation of a photoactivatable reagent that is a polymerization initiator.
  • the applied composition can be treated with UV light to activate the polymerization initiator.
  • Particles of bioactive agent can be associated with the coating to provide partially embedded particles using a variety of techniques.
  • a flexible hydrogel layer is formed on the surface of the expandable and collapsible structure.
  • an aqueous composition containing bioactive agent is disposed on the surface of the flexible hydrogel layer.
  • the water in the aqueous composition causes at least the surface of the flexible hydrogel layer to swell.
  • the swelling makes the flexible hydrogel layer at least partially permeable to the bioactive agent deposited on the hydrogel layer, and bioactive agent move into the polymeric material of hydrogel layer.
  • water can then be removed, such as by evaporation, heating, or vacuum. Removal of water causes the hydrogel layer to shrink from a swollen state, physically constrain the bioactive agent, and results in the partial embedding of a substantial portion of the bioactive agent deposited on the surface of the hydrogel layer.
  • the present invention provides methods and devices for the delivery of a bioactive agent to a target tissue.
  • the present invention contemplates various types of medical devices that include an expandable and collapsible structure from which a bioactive agent can be released.
  • the insertable medical device is a balloon catheter.
  • the bioactive agent is associated with an expandable and collapsible surface of an insertable medical device via a coated material. The device can be inserted into a subject to place the expandable and collapsible surface in contact with a target tissue to which the bioactive agent can be transferred.
  • the expandable and collapsible surface can be expanded, causing release or dissociation of the bioactive agent (e.g., in microparticulate form) from coating on the surface of the expandable and collapsible structure.
  • the expandable and collapsible surface can include a biodegradable coated material that is released from the expandable collapsible structure when it is expanded, resulting in the transfer of the biodegradable coated material along with the bioactive agent (e.g.,
  • the expandable and collapsible structure of the device can be formed from any material, or combination of materials, capable of expanding, and suitable for use within the body.
  • the one or more material(s) can be based on use of the device.
  • the expandable and collapsible materials are compliant and flexible materials, such as elastomers (polymers with elastic properties). Elastomers are typically thermoplastic polymers.
  • Exemplary elastomers can be formed from various polymers including polyurethanes and polyurethane copolymers, polyethylene, styrene-butadiene copolymers, polyisoprene, isobutylene-isoprene copolymers (butyl rubber), including halogenated butyl rubber, butadiene-styrene- acrylonitrile copolymers, silicone polymers, fluorosilicone polymers,
  • polycarbonates polyamides, polyesters, polyvinyl chloride, polyether-polyester copolymers, and polyether-polyamide copolymers.
  • the expandable and collapsible structure can be made of a single elastomeric material, or a combination of materials.
  • the expandable and collapsible structure can be manufactured by an extrusion process, so that the elastic structure is a single layer of material, or co-extruded to form a multi-layered material.
  • the elastic structure can have a thickness suitable for the desired application and device.
  • the thickness of an elastic structure can be in the range of about 5 ⁇ to about 100 ⁇ .
  • the insertable medical device has an expandable and collapsible structure that includes or is a balloon, e.g., an angioplasty balloon.
  • a balloon e.g., an angioplasty balloon.
  • Suitable bioactive agents that can be released to the vasculature include an antiproliferative agent, an antiinflamatory agent, an antiplatelet agent, or plurality thereof.
  • Suitable antiproliferative agents include paclitaxel.
  • Balloon catheters are commonly used in angioplasty procedures for the treatment of arteries that are diseased. Balloon angioplasty generally involves the dilation or reopening of blocked intraluminal channels.
  • Balloon catheter constructions are well known in the art and are described in various documents, for example, U.S. Patent Nos. 4,195,637, 5,041,089, 5,087,246, 5,318,587, 5,382,234, 5,571,089, 5,776,101, 5,807,331, 5,882,336, 6,394,995, 6,517,515, 6,623,504, 6,896,842, and 7,163,523.
  • Balloon catheters generally include four portions, the balloon, catheter shaft, guidewire, and manifold.
  • a balloon catheter generally includes an elongated catheter shaft with the inflatable balloon attached to a distal section of the catheter shaft. At a proximal end of the catheter shaft, there is typically a manifold. At the manifold end, placement of the catheter can be facilitated using a guidewire. Guidewires are small and
  • the catheter with balloon portion is then fed over the guidewire until the balloon reaches the target location in the vessel.
  • the balloon is then inflated when the catheter reaches the targeted constriction to thereby apply the requisite mechanical force to cause vessel dilation.
  • the manifold can also control the fluid introduction within shaft for expansion of the balloon.
  • the balloon is typically inserted into the arterial lumen of a patient and advanced through the lumen in an unexpanded state.
  • a folding process may involve creating "arms" of the balloon material and folding these arms inward (towards the catheter axis) to compact the balloon material.
  • a folding pattern there will be portions of the balloon material (when the balloon is folded and compacted) that face the outside, and portions of the balloon material that face the inside, the inner- facing portions representing "protected" surfaces.
  • the inner-facing surfaces of the balloon material include the present coating.
  • the balloon is typically inflated using a fluid, which is injected through an inflation port.
  • a fluid which is injected through an inflation port.
  • the mechanics of fluid transfer and introduction within balloons vary according to the specific design of the catheter, and are well know in the art.
  • Exemplary thicknesses for the walls of catheter balloons are in the range of about 5 ⁇ to about 20 ⁇ .
  • the actual thickness of the balloon wall may depend on one or more factors, such as the desired pliability of the balloon, the overall profile of the balloon on the catheter (low profile devices may use thin walled balloons), the pressure rating for the balloon wall, or the expansion properties of the balloon.
  • a balloon with a thin wall is used, so as to accommodate the increase in thickness when a coating is formed on the surface.
  • Catheter balloon construction is described in various references, for example, U.S. Patent Nos. 4,490,421, 5,556,383, 6,210,364, 6,168,748, 6,328,710, and 6,482,348.
  • Molding processes are typically performed for balloon construction. Balloons fabricated by such processes are suitable as substrates for the coatings according to the present invention.
  • an extruded polymeric tube is radially and axially expanded at elevated temperatures within a mold having the desired shape of the balloon.
  • the balloon can be subjected to additional treatments following the molding process.
  • the formed balloon can be subjected to additional heating steps to reduce shrinkage of the balloon.
  • Silicone tubing (inner diameter: 0.125 inch; outer diameter: 0.188 inch; wall: 0.0315 inch; Cole-Parmer Instrument Co.) is obtained and cut into 1.5 inch lengths. The silicone tubing pieces are then placed individually in a 4mL amber glass vial filled with 4mL of PBS (phosphate buffer saline) pH-7.4, which is preheated in a water bath to 37°C.
  • PBS phosphate buffer saline
  • a coated (see, e.g., the Examples), deflated, folded balloon is placed in an 8mL vial (holding 8mL of phosphate buffer saline at pH 7.4, which is preheated in a water bath to 37°C) for soaking for 4 min.
  • the balloon is then slid into the inner lumen of the silicone tube (submerged inside 4mL vial) and then expanded for 30sec at 4 arm. Pressure is then released and the balloon is removed from the tubing.
  • the tubing is submerged in 4mL of a mixture of 0.1% glacial acetic acid in methanol for 24 hours. A 350 juL aliquot of the extraction media is then transferred to 96 well plate for drug content measurement by UV (@ 232 nm).
  • a coating composition for forming a hydrogel coated layer on a catheter balloon can be as follows.
  • a hydrogel coating solution is prepared using photo- polyacrylamide at 5 mg/mL, photo-poly(vinylpyrrolidone) (as described in Example 4 of U.S. Pat. No. 5,414,075) at 25 mg/mL, polyvinylpyrrolidone) K90 (BASF) at 10 mg/mL, and 4,5-bis(4-benzoylphenylmethyleneoxy) benzene- 1, 3 -disulfonic acid (as described in U.S. Patent No. 6,278,018 (Example 1)) at 0.25 mg/mL, is dissolved into a mixture of IPA and water (15% IP A/85% water).
  • bioactive agent refers to an inorganic or organic molecule, which can be synthetic or natural, that causes a biological effect when administered in vivo to an animal, including but not limited to birds and mammals, including humans.
  • a partial list of bioactive agents is provided below. One may choose any one of the bioactive agents to be included alone, or in combination with any other bioactive agent.
  • a comprehensive listing of bioactive agents, in addition to information of the water solubility of the bioactive agents, can be found in The Merck Index, Thirteenth Edition, Merck & Co. (2001 ).
  • the bioactive agent(s) can be, for example, one or more of the following classes of agents: ACE inhibitors, actin inhibitors, analgesics, anesthetics, antihypertensives, anti polymerases, antisecretory agents, antibiotics, anti-cancer substances, anti-cholinergics, anti-coagulants, anti-convulsants, anti-depressants, anti-emetics, antifungals, anti-glaucoma solutes, antihistamines, antihypertensive agents, anti-inflammatory agents (such as NSAIDs), anti metabolites, antimitotics, antioxidizing agents, anti-parasite and/or anti-Parkinson substances,
  • the microparticulate include an antiproliferative agent.
  • the antiproliferative agent can be an anti-angiogenesis agent.
  • microparticulate include an anti-inflammatory agent.
  • the microparticulate include a cell response modifier.
  • cell response modifiers are the interleukins, interleukin inhibitors or interleukin receptors, including interleukin 1 through interleukin 10; interferons, including alpha, beta and gamma; hematopoietic factors, including erythropoietin, granulocyte colony stimulating factor, macrophage colony stimulating factor and granulocyte-macrophage colony stimulating factor; tumor necrosis factors, including alpha and beta; transforming growth factors (beta), including beta-1 , beta-2, beta-3, inhibin, activin, and DNA that encodes for the production of any of these proteins.
  • interleukins interleukin inhibitors or interleukin receptors, including interleukin 1 through interleukin 10
  • interferons including alpha, beta and gamma
  • hematopoietic factors including erythropoietin, granulocyte colony stimulating factor, macrophage colony stimulating factor and granulocyte-macrophag
  • statins examples include lovastatin, pravastatin, simvastatin, fluvastatin, atorvastatin, cerivastatin, rosuvastatin, and superstatin.
  • steroids examples include glucocorticoids such as cortisone,
  • hydrocortisone dexamethasone, betamethasone, prednisone, prednisolone, methylprednisolone, triamcinolone, beclomethasone, fludrocortisone, and aldosterone; sex steroids such as testosterone, dihydrotestosterone, estradiol, diethylstilbestrol, progesterone, and progestins.
  • the bioactive agent can provide antirestenotic effects, such as
  • the bioactive agent can be selected from anti-inflammatory agents,
  • immunosuppressive agents include, for example, actinomycin D, angiopeptin, c-myc antisense, paclitaxel, taxane, and the like.
  • bioactive agents having antithrombotic effects include heparin, heparin derivatives, sodium heparin, low molecular weight heparin, hirudin, lysine, prostaglandins, argatroban, forskolin, vapiprost, prostacyclin and prostacyclin analogs, D-phe-pro-arg-chloromethylketone (synthetic antithrombin), dipyridamole, glycoprotein lib/IIIa platelet membrane receptor antibody, coprotein lib/IIIa platelet membrane receptor antibody, recombinant hirudin, thrombin inhibitor (such as commercially available from Biogen), chondroitin sulfate, modified dextran, albumin, streptokinase, tissue plasminogen activator (TP A), urokinase, nitric oxide inhibitors, and the like.
  • heparin heparin derivatives, sodium heparin, low molecular weight heparin, hir
  • the bioactive agent can also be an inhibitor of the GPIIb-IIIa platelet receptor complex, which mediates platelet aggregation.
  • GPIIb/IIIa inhibitors can include monoclonal antibody Fab fragment c7E3, also know as abciximab
  • the bioactive agent can be a surface adhesion molecule or cell- cell adhesion molecule.
  • Exemplary cell adhesion molecules or attachment proteins such as extracellular matrix proteins, include fibronectin, laminin, collagen, elastin, vitronectin, tenascin, fibrinogen, thrombospondin, osteopontin, von Willibrand Factor, bone sialoprotein (and active domains thereof), and hydrophilic polymers such as hyaluronic acid, chitosan and methyl cellulose, and other proteins, carbohydrates, and fatty acids.
  • Other cell-cell adhesion molecules include N- cadherin and P-cadherin and active domains thereof.
  • An antiproliferative agent such as sirolimus or paclitaxel, can inhibit neointimal proliferation at a dilated site.
  • An antithrombotic agent such as heparin, can inhibit clotting.
  • the present device and method can release an effective amount of the bioactive agent at the desired site.
  • the method and device can release about 10% or more of the bioactive agent originally associated with the device, about 20% or more, about 30% or more, about 40% or more, about 50% or more, about 60% or more, about 70% or more, about 80% or more, or about 90% or more.
  • the amount of bioactive agent transferred is in the range of about 30% to about 90%.
  • the bioactive agent can be formulated with an excipient.
  • Excipients can improve the stability of the bioactive agent within the coating, or can change physical properties of the bioactive agent.
  • exemplary excipients include glycerol, diethylene glycol, sorbitol, sorbitol esters, maltitol, sucrose, fructose, invert sugars, corn syrup, and mixtures thereof.
  • the amount and type of excipient(s) can be based on known standards and techniques.
  • the excipient can be an antioxidant.
  • the coating can include an imaging component.
  • An imaging component can be detectable using common imaging techniques and suitable for use in the inventive methods. These agents can be capable of allowing imaging of a desired site in the body, e.g., an intravascular target site.
  • imaging agents include substances having a label that is detectable in vivo, e.g., antibodies attached to fluorescent labels, paramagnetic materials, such as iron oxide, Gd, or Mn, or a radioisotope.
  • Imaging components can be detected by paramagnetic resonance imaging, ultrasonic imaging, or other suitable detection techniques.
  • the bioactive agent can be in the form of a microparticulate.
  • microparticulate can be any three-dimensional particle of size and shape sufficient to be associated with the substrate via coating materials, and then dissociated upon its expansion of the substrate.
  • the microparticulate can have a spherical, or substantially spherical shape, such as those that are formed from synthetic polymeric materials.
  • the elastic structure of the device is associated with spherical or substantially spherical microparticulate, which is herein referred to as a "microsphere.”
  • microparticulate can be used that have noticeably non-spherical shapes or irregular shapes (for example, when examined by microscopy).
  • the microparticulate can have curved surfaces, flat surfaces, or
  • the expandable and collapsible structure can be associated with a plurality of microparticulate of a combination of different sizes and/or shapes.
  • Microparticulate can be in the form of microcrystals or particles that otherwise have crystalline shapes or configurations.
  • Microparticulate with crystalline shapes may be composed of bioactive agent molecules that are arranged in the microparticulate in an orderly repeating pattern extending in all three spatial dimensions. Crystalline shapes can typically be observed under the microscope. Microcrystals may be observed as having rod-like, filament-like, sliver-like, or needle-like shapes.
  • microparticulate may also be observed (or exist in) as aggregated or clumped structures.
  • aggregates of microparticulate having rod-like, filament-like, sliver-like, or needlelike shapes can be associated with the coating materials.
  • microparticulate associated with the expandable and collapsible structure have a greatest average dimension that is less than about 50 um.
  • microparticulate can have an elongated shape, with a length along the elongate axis of less than about 50 um. Size analysis, such as by microscopy, can be used to assess irregular shaped microparticulate or microcrystal.
  • the microparticulate have a greatest average dimension in the range of about 100 nm to about 50 ⁇ , about 100 nm to about 25 ⁇ , about 100 nm to about 20 ⁇ , or about 100 ⁇ to about 10 ⁇ .
  • the microparticulate have a spherical or substantially spherical shape with an average diameter of about 100 nm or larger.
  • the microparticulate associated with the expandable and collapsible structure can have an average diameter in the range of about 100 nm to about 50 ⁇ , about 150 nm to about 25 ⁇ , about 200 nm to about 20 ⁇ , or about 0.3 ⁇ to about 10 ⁇ .
  • microparticulate associated with the expandable and collapsible structure have an average diameter ("dn", number average) that is less than about 50 ⁇ . Also, in many aspects, the microparticulate can have an average diameter of about 100 nm or larger. For example, the microparticulate associated with the expandable and collapsible structure can have an average diameter in the range of about 100 nm to about 50 ⁇ , about 150 nm to about 25 ⁇ , about 200 nm to about 20 ⁇ , or about 0.3 ⁇ to about 10 ⁇ .
  • microparticulate is associated with the expandable and collapsible structure
  • microparticulate is immobilized in a coating on the surface of the elastic structure, it is generally desirable to utilize microparticulate having an average diameter that is smaller than the thickness of the coating.
  • the microparticulate associated with the elastic surface can also have a low size polydispersity.
  • Low size dispersity means that there is little variation in the size of the microparticulate in the population of microparticulate (as compared to a high size dispersity, which means that there is considerable variation in the size of the microparticulate population).
  • the microparticulate can be formed completely or substantially of a selected bioactive agent for treatment or prevention of a condition.
  • the microparticulate can be formed from a combination of bioactive agents (e.g., two or more different bioactive agents).
  • the microparticulate can be formed from a bioactive agent and another component that is not intended to provide a therapeutic effect to the subject, such as a polymer that can modulate the release of the bioactive agent from the microparticulate.
  • the microparticulate include two or more components, such as two or more polymers that modulate the release of the bioactive agent from the microparticulate.
  • Components of the microparticulate can be in mixture with one another in a portion of, or all of, the microparticulate. Alternatively, the components can be entirely or substantially separated from one another in the microparticulate.
  • the microparticulate can be formed including a substantially homogenous mixture of a bioactive agent and a release-modulating polymer.
  • the microparticulate can be formed including a bioactive agent core and a release-modulating polymer shell around the core. The preparation of paclitaxel microparticles has been described in U.S. Patent No. 6,610,317.
  • a liquid composition of a bioactive agent in a solvent can be precipitated by addition of an excess of a non-solvent (e.g., water or an aqueous composition).
  • a non-solvent e.g., water or an aqueous composition.
  • the solvent can be removed from the liquid composition by phase separation, or a comparable technique.
  • the precipitated composition can then be subjected to comminution, which refers to mechanical process that can reduce the size of the precipitated particulates. For example, wet milling can be used to reduce particle size in a liquid composition and produce microparticulate.
  • the precipitated bioactive agent can then be filtered and washed with the non-solvent.
  • a liquid composition of the bioactive agent and solvent can be atomized and spray deposited on a substrate, and during the process the solvent is evaporated from the droplets.
  • concentration of the bioactive agent, the droplet size, and the evaporation of the solvent can be determined to provide desired microparticulate formation.
  • a spray drying process is performed by directly spraying a liquid composition of the bioactive agent onto a coated layer (for example, the flexible hydrogel layer or a biodegradable material layer) of the device.
  • a coated layer for example, the flexible hydrogel layer or a biodegradable material layer
  • the microparticulate is formed on the coated layer as the solvent from the droplets evaporates.
  • the sprayed composition may also include a liquid that causes the swelling of the hydrogel layer. Therefore, as the
  • microparticulate form they also move into the hydrogel material. As the non-solvent evaporates, the hydrogel shrinks and the microparticulate become constrained by the hydrogel material and at least partially embedded in the flexible hydrogel coating.
  • the microparticulate is composed of higher molecular weight bioactive agents, such as polypeptides.
  • Degradable microparticulate can be prepared incorporating various biologically active agents by established techniques, for example, the solvent evaporation technique (see, for example, Wiehert, B. and Rohdewald, P. J
  • the microparticulate includes a bioactive agent and a polymer, wherein the microparticulate has a structure that includes an inner portion including the bioactive agent and an outer portion including polymer.
  • the microparticulate can have a bioactive agent core and polymer shell.
  • the core of the microparticulate is formed substantially or entirely of bioactive agent, and the shell includes a biodegradable polymer.
  • the core of the microparticulate is includes a bioactive agent and a first polymer
  • the shell includes a second polymer, such as a
  • biodegradable polymer For example, the first and second polymers are selected from synthetic biodegradable polymers.
  • the inner portion (e.g., core) of the microparticulate includes at least most of, if not all, of the bioactive agent present in the microparticulate.
  • Various techniques can be used to prepare microparticulate having inner and outer portions (see, for example, Pekarek, KJ. (1994) Nature 367:258-60). Some techniques are based on phase separation of a polymer mixture. Many phase separation techniques also involve solvent evaporation.
  • Microparticulate including an inner portion and an outer portion can be prepared by first preparing a first composition that includes the first polymer and the bioactive agent.
  • the first composition can be treated to provide a homogenous suspension of the first polymer and the bioactive agent.
  • the homogenized first composition can then be combined with a second composition that includes the second polymer.
  • the mixture of the first and second compositions can then be homogenized.
  • microparticulate can be formed by combining the composition with a solution that promotes formation of the microparticulate, such as a polyvinylalcohol-containing solution.
  • a solution that promotes formation of the microparticulate such as a polyvinylalcohol-containing solution.
  • microparticulate can then be recovered by, for example, centrifugation, and then optionally washed, and frozen or lyophilized.
  • the inner portion of the microparticulate include a synthetic biodegradable copolymer, such as poly(lactide-co-glycolide) and an outer portion of the microparticulate include a synthetic biodegradable homopolymer, such as poly(lactide).
  • a synthetic biodegradable copolymer such as poly(lactide-co-glycolide)
  • an outer portion of the microparticulate include a synthetic biodegradable homopolymer, such as poly(lactide).
  • the microparticulate can also include one or more non-polymeric compounds to control release of the bioactive agent.
  • the microparticulate can also include one or more non-polymeric compounds to control release of the bioactive agent.
  • the microparticulate can also include one or more non-polymeric compounds to control release of the bioactive agent.
  • microparticulate can include a soluble metal or metal salt to control release of the bioactive agent.
  • exemplary metal salts inorganic metal chlorides, fluorides, and oxides.
  • the metal salt can be slightly soluble in water.
  • the microparticulate can be partially or wholly coated with a metal salt.
  • the elastic surface is associated with two or more sets of microparticulate.
  • the use of two or more sets of microparticulate may allow a particular bioactive agent to be released at different rates after the microparticulate have been transferred to tissue, or may allow two different types of bioactive agents to be released to a subject.
  • a first bioactive agent can be released from a first set of microparticulate and a second bioactive agent can be released from a second set of microparticulate.
  • Two sets of microparticulate can be used if it is desired to deliver two bioactive agents which are mutually incompatible in a particular environment, for example, as hydrophobic and hydrophilic drugs are incompatible in either a polar or non-polar solvent.
  • the first bioactive agent can be a hydrophobic drug present in a first set of microparticulate
  • the second bioactive agent can be a hydrophilic drug present in a second set of microparticulate.
  • Useful degradable polymers or degradable copolymers for hydrophobic drugs have a high lactide or high caprolactone content; whereas useful degradable polymers or degradable copolymers for hydrophilic drugs have high glycolide content.
  • Example 1 The Present Barrier Layer Increases Drug Delivery to Tissue
  • An embodiment of the present barrier layer a coating composition of 50 wt- % dodecanoic acid and 50 wt-% oleic acid, increased transfer of paclitaxel from a balloon catheter to arterial tissue in an ex-vivo model.
  • the expandable and collapsible surface of the balloon of a balloon catheter was provided with a flexible hydrogel coating with associated paclitaxel
  • the balloon catheter was obtained from Minnesota Medtec (Maple Grove, MN).
  • the expandable and collapsible structure of the balloon was made from nylon with a balloon wall thickness of 5-10 ⁇ .
  • a hydrogel coating solution was prepared using photo-polyacrylamide (as described in U.S. Patent No. 6,007,833, which was weighed and dissolved into a mixture of IP A and water (50% IP A/50% water (v/v)) at a concentration of 10 mg/mL.
  • the balloon was coated in the photo-polyacrylamide coating solution using a dip process with a withdrawal rate of 0.5 cm/s. After the hydrogel coating solution was applied to the balloon, it was subjected to UV cure.
  • the coated balloon was placed in front of a Dymax 2000-EC Series UV Floodlamb with a 400 Watt metal halide bulb, approximately 20 cm from light source, illuminated for three minutes, and then removed.
  • paclitaxel microparticulate was prepared using a wet milling process. Briefly, neat drug was added directly to DI water at 20 mg/mL. The precipitated paclitaxel particulates were then milled in water to reduce the particle size to ⁇ l-3 jum. The drug/water suspension was tumble milled in a glass jar with ceramic beads. The suspension was milled for 16 hours (overnight) at approximately 100 rpm. The resulting suspension was then applied to the photo-polymer coated surface by pipetting a known volume of drug suspension (typically 20 ⁇ ). The pipetted droplet was evenly distributed over the balloon surface by rotating the balloon until the solvent was visibly dry. Then, the balloon was pleated and folded. The present lipid coating was then applied by dipping the folded, coated, paclitaxel bearing catheter balloon into the melted lipid coating composition at 40 °C at 0.5 to 1 cm/sec. After dipping the coated balloon was kept at room
  • the coated balloon was cooled at -20 °C and a protective sheath was put over the coating.
  • porcine artery was obtained and cut into 1.5 inch lengths. The porcine artery pieces were then placed in a 4mL amber glass vial filled with 4mL of PBS (phosphate buffered saline) at pH 7.4, which was preheated in a water bath to 37°C.
  • PBS phosphate buffered saline
  • a deflated, folded balloon was placed in an 8mL vial that had been filled with 8mL of PBS at pH 7.4 and preheated in a water bath to 37°C and soaked for 4 min.
  • the balloon was put through a 7 French guide catheter. After it exited the guide catheter it was inserted into the artery.
  • the balloon was slid into the inner lumen of the porcine artery (submerged inside 4mL vial) and then expanded for 30sec at 4 arm. Pressure was then released and the balloon was removed from the porcine artery.
  • the porcine artery was submerged in 4mL of a mixture of 0.1 % glacial acetic acid in methanol for 24 hours. A 1 mL aliquot of the extraction media was then transferred to 96 well plate for drug content measurement by UV. The amounts of paclitaxel transferred to the porcine artery were measured and reported.
  • the present lipid coating significantly decreased release of particles from a coated catheter balloon in simulated use testing ( Figure 2).
  • the catheter was put through a tortuous path, inflated, deflated, and retracted.
  • Data set 1 shows release of particles in the absence of the present lipid coating when the particles are embedded in a hydrogel coating.
  • Data set two illustrates significantly reduced release of particles when the hydrogel coating including drug particles has been covered by an embodiment of the present lipid coating composition (50 wt-% dodecanoic acid and
  • Data sets three and four illustrates particle release from a first and second catheter system in the absence of either the hydrogel or the lipid coating. The results were normalized for a 3.5 x 15mm balloon size.
  • Figure 3 illustrates that the present lipid coating increased transfer of drug to tissue as well as decreasing loss of drug in ex vivo testing.
  • the middle bar in each set shows the amount of drug found in a location when using a catheter coated with an embodiment of the present lipid coating composition (50 wt-% dodecanoic acid and 50 wt-% oleic acid).
  • the left bar in each set represents location of drug when the catheter included the hydrogel coating but no fatty acid coating.
  • the right bar in each set represents the location of drug when the fatty acid coating composition was 100 wt-% dodecanoic acid.
  • the data illustrates that more drug is delivered to the tissue and less is lost in transfer or unaccounted for with use of the present lipid coating composition.
  • the term “configured” describes a system, apparatus, or other structure that is constructed or configured to perform a particular task or adopt a particular configuration.
  • the term “configured” can be used interchangeably with other similar phrases such as arranged and configured, constructed and arranged, adapted and configured, adapted, constructed, manufactured and arranged, and the like.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Materials For Medical Uses (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
EP11733953.1A 2010-06-30 2011-06-30 Lipidbeschichtung für medizinische vorrichtungen zur freisetzung bioaktiver wirkstoffe Active EP2588157B1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36021210P 2010-06-30 2010-06-30
PCT/US2011/042553 WO2012003293A1 (en) 2010-06-30 2011-06-30 Lipid coating for medical devices delivering bioactive agent

Publications (2)

Publication Number Publication Date
EP2588157A1 true EP2588157A1 (de) 2013-05-08
EP2588157B1 EP2588157B1 (de) 2020-03-18

Family

ID=44509904

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11733953.1A Active EP2588157B1 (de) 2010-06-30 2011-06-30 Lipidbeschichtung für medizinische vorrichtungen zur freisetzung bioaktiver wirkstoffe

Country Status (5)

Country Link
US (1) US8927000B2 (de)
EP (1) EP2588157B1 (de)
JP (1) JP5984806B2 (de)
CA (1) CA2803361C (de)
WO (1) WO2012003293A1 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010045477A2 (en) * 2008-10-16 2010-04-22 Obalon Therapeutics, Inc. Intragastric volume-occupying device and method for fabricating same
CA3037168A1 (en) 2009-12-18 2011-06-23 Interface Biologics, Inc. Local delivery of drugs from self assembled coatings
WO2012096787A1 (en) * 2010-12-30 2012-07-19 Surmodics, Inc. Double wall catheter for delivering therapeutic agent
US10213529B2 (en) 2011-05-20 2019-02-26 Surmodics, Inc. Delivery of coated hydrophobic active agent particles
US9861727B2 (en) 2011-05-20 2018-01-09 Surmodics, Inc. Delivery of hydrophobic active agent particles
CA2861314C (en) * 2012-01-18 2021-03-16 Surmodics, Inc. Lubricious medical device coating with low particulates
JP6438406B2 (ja) 2012-11-05 2018-12-12 サーモディクス，インコーポレイテッド 疎水性生理活性物質を送達するための組成物および方法
US9439892B2 (en) 2013-05-16 2016-09-13 Surmodics, Inc. Macrolide particulates, methods for preparation, and medical devices associated therewith
US11806266B2 (en) 2014-03-19 2023-11-07 Purewick Corporation Apparatus and methods for receiving discharged urine
US11376152B2 (en) 2014-03-19 2022-07-05 Purewick Corporation Apparatus and methods for receiving discharged urine
US10952889B2 (en) 2016-06-02 2021-03-23 Purewick Corporation Using wicking material to collect liquid for transport
US11090183B2 (en) 2014-11-25 2021-08-17 Purewick Corporation Container for collecting liquid for transport
US9492594B2 (en) * 2014-07-18 2016-11-15 M.A. Med Alliance SA Coating for intraluminal expandable catheter providing contact transfer of drug micro-reservoirs
US11406742B2 (en) 2014-07-18 2022-08-09 M.A. Med Alliance SA Coating for intraluminal expandable catheter providing contact transfer of drug micro-reservoirs
US10124088B2 (en) 2014-09-29 2018-11-13 Surmodics, Inc. Lubricious medical device elements
CN104874090A (zh) * 2015-03-20 2015-09-02 深圳市信立泰生物医疗工程有限公司 一种新型药物洗脱球囊导管
CN108135836A (zh) * 2015-08-11 2018-06-08 Ptt控股公司 递送装置
US10342898B2 (en) 2015-12-29 2019-07-09 Surmodics, Inc. Lubricious coatings with surface salt groups
US11174447B2 (en) 2015-12-29 2021-11-16 Surmodics, Inc. Lubricious coatings with surface salt groups
US10098846B2 (en) 2016-03-31 2018-10-16 Surmodics, Inc. Drug-containing particulate composition with cationic agent, associated medical devices, and methods for treatment
US11147952B2 (en) * 2016-04-28 2021-10-19 Medtronic Vascular, Inc. Drug coated inflatable balloon having a thermal dependent release layer
USD928946S1 (en) 2016-06-02 2021-08-24 Purewick Corporation Urine receiving apparatus
US10376406B2 (en) 2016-07-27 2019-08-13 Purewick Corporation Male urine collection device using wicking material
US10973678B2 (en) 2016-07-27 2021-04-13 Purewick Corporation Apparatus and methods for receiving discharged urine
US11123459B2 (en) 2016-12-16 2021-09-21 Surmodics, Inc. Hydrophobic active agent particle coatings and methods for treatment
US10898446B2 (en) 2016-12-20 2021-01-26 Surmodics, Inc. Delivery of hydrophobic active agents from hydrophilic polyether block amide copolymer surfaces
CA3098570C (en) 2018-05-01 2023-09-26 Purewick Corporation Fluid collection devices, related systems, and related methods
CA3098680A1 (en) 2018-05-01 2019-11-07 Purewick Corporation Fluid collection garments
CA3098571C (en) 2018-05-01 2023-09-26 Purewick Corporation Fluid collection devices, systems, and methods
CN112638436A (zh) 2018-05-22 2021-04-09 界面生物公司 用于将药物递送至血管壁的组合物和方法
CA3114461A1 (en) * 2018-10-15 2020-04-23 M.A. Med Alliance SA Coating for intraluminal expandable catheter providing contact transfer of drug micro-reservoirs
CN111388154B (zh) * 2018-12-28 2023-01-03 元心科技(深圳)有限公司 可吸收植入医疗器械
USD929578S1 (en) 2019-06-06 2021-08-31 Purewick Corporation Urine collection assembly
CN110292701B (zh) * 2019-06-27 2021-11-16 山东瑞安泰医疗技术有限公司 一种药物洗脱球囊导管及其制备方法
US12048643B2 (en) 2020-05-27 2024-07-30 Purewick Corporation Fluid collection assemblies including at least one inflation device and methods and systems of using the same
USD967409S1 (en) 2020-07-15 2022-10-18 Purewick Corporation Urine collection apparatus cover
US11801186B2 (en) 2020-09-10 2023-10-31 Purewick Corporation Urine storage container handle and lid accessories
US12042423B2 (en) 2020-10-07 2024-07-23 Purewick Corporation Fluid collection systems including at least one tensioning element
US12048644B2 (en) 2020-11-03 2024-07-30 Purewick Corporation Apparatus for receiving discharged urine
US12070432B2 (en) 2020-11-11 2024-08-27 Purewick Corporation Urine collection system including a flow meter and related methods
AU2022211357B2 (en) 2021-01-19 2024-08-01 Purewick Corporation Variable fit fluid collection devices, systems, and methods
JP2023553620A (ja) 2021-02-26 2023-12-25 ピュアウィック コーポレイション 管開口とバリアとの間に排水受けを有する流体収集装置、ならびに関連するシステムおよび方法
US11938054B2 (en) 2021-03-10 2024-03-26 Purewick Corporation Bodily waste and fluid collection with sacral pad
US12029677B2 (en) 2021-04-06 2024-07-09 Purewick Corporation Fluid collection devices having a collection bag, and related systems and methods
CN114832214A (zh) * 2022-04-25 2022-08-02 上海畅德医疗科技有限公司 一种药物球囊导管及其制备方法和用途

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH616337A5 (de) 1977-10-21 1980-03-31 Schneider Medintag Ag
US4490421A (en) 1983-07-05 1984-12-25 E. I. Du Pont De Nemours And Company Balloon and manufacture thereof
US5041089A (en) 1987-12-11 1991-08-20 Devices For Vascular Intervention, Inc. Vascular dilation catheter construction
US5087246A (en) 1988-12-29 1992-02-11 C. R. Bard, Inc. Dilation catheter with fluted balloon
US5318587A (en) 1989-08-25 1994-06-07 C. R. Bard, Inc. Pleated balloon dilatation catheter and method of use
US5843089A (en) 1990-12-28 1998-12-01 Boston Scientific Corporation Stent lining
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5674192A (en) * 1990-12-28 1997-10-07 Boston Scientific Corporation Drug delivery
ES2071279T3 (es) 1990-10-04 1995-06-16 Schneider Europ Ag Cateter de balon de dilatacion.
US5102402A (en) 1991-01-04 1992-04-07 Medtronic, Inc. Releasable coatings on balloon catheters
US5195969A (en) 1991-04-26 1993-03-23 Boston Scientific Corporation Co-extruded medical balloons and catheter using such balloons
US5500180A (en) 1992-09-30 1996-03-19 C. R. Bard, Inc. Method of making a distensible dilatation balloon using a block copolymer
US5414075A (en) 1992-11-06 1995-05-09 Bsi Corporation Restrained multifunctional reagent for surface modification
US5382234A (en) 1993-04-08 1995-01-17 Scimed Life Systems, Inc. Over-the-wire balloon catheter
US5344402A (en) 1993-06-30 1994-09-06 Cardiovascular Dynamics, Inc. Low profile perfusion catheter
US6896842B1 (en) 1993-10-01 2005-05-24 Boston Scientific Corporation Medical device balloons containing thermoplastic elastomers
CA2160487C (en) 1994-02-17 2003-09-23 Lixiao Wang Process improvements for preparing catheter balloons
ES2141928T5 (es) 1994-03-02 2009-04-16 Boston Scientific Limited Balones de elastomero de copolimero en bloques para cateter.
AU2359395A (en) 1994-04-20 1995-11-16 Ronald J. Solar Active perfusion dilatation catheter
US6911216B1 (en) * 1994-10-12 2005-06-28 Genzyme Corporation Targeted delivery via biodegradable polymers
US5667493A (en) 1994-12-30 1997-09-16 Janacek; Jaroslav Dilation catheter
ES2153984T3 (es) 1995-11-08 2001-03-16 Scimed Life Systems Inc Procedimiento de formacion de balon mediante estrechamiento por estirado en frio.
US6143037A (en) 1996-06-12 2000-11-07 The Regents Of The University Of Michigan Compositions and methods for coating medical devices
EP0842657A1 (de) 1996-11-19 1998-05-20 OctoPlus B.V. Mikrosphären zur gesteuerten Freisetzung und Verfahren zur Herstellung dieser Mikrosphären
EP0980280B1 (de) 1997-10-01 2005-02-09 Medtronic Ave, Inc. Wirstoffabgabe und gentherapiesystem
US6517515B1 (en) 1998-03-04 2003-02-11 Scimed Life Systems, Inc. Catheter having variable size guide wire lumen
US6007833A (en) 1998-03-19 1999-12-28 Surmodics, Inc. Crosslinkable macromers bearing initiator groups
US6450989B2 (en) 1998-04-27 2002-09-17 Artemis Medical, Inc. Dilating and support apparatus with disease inhibitors and methods for use
CA2330134A1 (en) 1998-05-15 1999-11-25 Medgination, Inc. Enhanced balloon dilatation system
US7947015B2 (en) 1999-01-25 2011-05-24 Atrium Medical Corporation Application of a therapeutic substance to a tissue location using an expandable medical device
US6673053B2 (en) 1999-05-07 2004-01-06 Scimed Life Systems, Inc. Hydrophilic lubricity coating for medical devices comprising an antiblock agent
US6610317B2 (en) 1999-05-27 2003-08-26 Acusphere, Inc. Porous paclitaxel matrices and methods of manufacture thereof
US6544579B1 (en) 1999-10-18 2003-04-08 Land O'lakes, Inc. Trans-isomer-free fat blend and a process for forming the trans-isomer-free fat blend
US6278018B1 (en) 1999-12-14 2001-08-21 Surmodics, Inc. Surface coating agents
US6703040B2 (en) 2000-01-11 2004-03-09 Intralytix, Inc. Polymer blends as biodegradable matrices for preparing biocomposites
US7261735B2 (en) 2001-05-07 2007-08-28 Cordis Corporation Local drug delivery devices and methods for maintaining the drug coatings thereon
US6638246B1 (en) 2000-11-28 2003-10-28 Scimed Life Systems, Inc. Medical device for delivery of a biologically active material to a lumen
US6623504B2 (en) 2000-12-08 2003-09-23 Scimed Life Systems, Inc. Balloon catheter with radiopaque distal tip
US7034037B2 (en) 2001-06-29 2006-04-25 Ethicon, Inc. Compositions and medical devices utilizing bioabsorbable polymeric waxes and rapamycin
US20030064965A1 (en) 2001-10-02 2003-04-03 Jacob Richter Method of delivering drugs to a tissue using drug-coated medical devices
EP1434571B1 (de) 2001-10-05 2005-05-11 SurModics, Inc. Beschichtungen mit immobilisierten partikeln sowie verwendungen derselben
CA2466432A1 (en) * 2001-11-08 2003-05-15 Atrium Medical Corporation Intraluminal device with a coating containing a therapeutic agent
DE10244847A1 (de) * 2002-09-20 2004-04-01 Ulrich Prof. Dr. Speck Medizinische Vorrichtung zur Arzneimittelabgabe
US7060051B2 (en) 2002-09-24 2006-06-13 Scimed Life Systems, Inc. Multi-balloon catheter with hydrogel coating
US7163523B2 (en) 2003-02-26 2007-01-16 Scimed Life Systems, Inc. Balloon catheter
EP1555278A1 (de) 2004-01-15 2005-07-20 Innocore Technologies B.V. Bioabbaubare Multiblock-Copolymere
WO2005099786A1 (en) 2004-04-06 2005-10-27 Surmodics, Inc. Coating compositions for bioactive agents
EP1755696A1 (de) 2004-05-12 2007-02-28 SurModics, Inc. Natürliche biologisch abbaubare polysaccharid-überzüge für medizinische artikel
WO2006002399A2 (en) 2004-06-24 2006-01-05 Surmodics, Inc. Biodegradable implantable medical devices, methods and systems
US7807750B2 (en) 2004-08-06 2010-10-05 Surmodics, Inc. Thermally-reactive polymers
US8124127B2 (en) * 2005-10-15 2012-02-28 Atrium Medical Corporation Hydrophobic cross-linked gels for bioabsorbable drug carrier coatings
US8312836B2 (en) 2004-09-28 2012-11-20 Atrium Medical Corporation Method and apparatus for application of a fresh coating on a medical device
ATE540705T1 (de) * 2005-09-21 2012-01-15 Surmodics Inc Überzüge und artikel mit natürlichen biologisch abbaubaren polysacchariden
CA2636716C (en) 2006-01-13 2014-12-23 Surmodics, Inc. Microparticle containing matrices for drug delivery
EP1981559B1 (de) * 2006-02-09 2016-11-23 B. Braun Melsungen AG Faltenballonbeschichtungsverfahren
EP1832289A3 (de) 2006-03-08 2007-12-12 Sahajanand Medical Technologies PVT. ltd Zusammensetzungen und Beschichtungen für implantierbare medizinische Vorrichtungen
US20070260054A1 (en) 2006-03-15 2007-11-08 Surmodics, Inc. Hydrophobic derivatives of natural biodegradable polysaccharides and uses thereof
CA2652314A1 (en) * 2006-05-17 2007-11-22 Ziscoat Nv Fatty acid triglycerides for making biocompatible coatings
EP2037977A2 (de) 2006-06-28 2009-03-25 SurModics, Inc. Wirkstoffbeschichtete matrizen mit partikeln
US8414526B2 (en) * 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8709827B2 (en) 2007-06-28 2014-04-29 Surmodics, Inc. Polypeptide microparticles
US20090105687A1 (en) 2007-10-05 2009-04-23 Angioscore, Inc. Scoring catheter with drug delivery membrane
US8951545B2 (en) * 2008-03-28 2015-02-10 Surmodics, Inc. Insertable medical devices having microparticulate-associated elastic substrates and methods for drug delivery
US9295820B2 (en) 2008-08-14 2016-03-29 Surmodics, Inc. Method and apparatus for coating balloon catheters
WO2010136604A1 (en) 2009-05-29 2010-12-02 Dsm Ip Assets B.V. Transfer matrix for transferring a bioactive agent to body tissue

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2012003293A1 *

Also Published As

Publication number Publication date
US8927000B2 (en) 2015-01-06
JP2013530020A (ja) 2013-07-25
US20120165786A1 (en) 2012-06-28
CA2803361A1 (en) 2012-01-05
EP2588157B1 (de) 2020-03-18
WO2012003293A1 (en) 2012-01-05
JP5984806B2 (ja) 2016-09-06
CA2803361C (en) 2020-07-21

Similar Documents

Publication Publication Date Title
EP2588157B1 (de) Lipidbeschichtung für medizinische vorrichtungen zur freisetzung bioaktiver wirkstoffe
US11020513B2 (en) Insertable medical devices having microparticulate-associated elastic substrates and methods for drug delivery
US8961457B2 (en) Catheter assembly with guard
US11318204B2 (en) Composition for intravascular delivery of therapeutic composition
US8668667B2 (en) Double wall catheter for delivering therapeutic agent
US10596355B2 (en) Catheter assembly

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20130130

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20131112

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20191015

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602011065671

Country of ref document: DE

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1245180

Country of ref document: AT

Kind code of ref document: T

Effective date: 20200415

Ref country code: IE

Ref legal event code: FG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200618

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200318

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200318

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20200318

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200318

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200318

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200619

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200318

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200618

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200318

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200812

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200318

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200318

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200318

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200318

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200318

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200318

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200718

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1245180

Country of ref document: AT

Kind code of ref document: T

Effective date: 20200318

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602011065671

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200318

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200318

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200318

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200318

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200318

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

26N No opposition filed

Effective date: 20201221

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200318

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200630

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20200630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200630

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200630

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200630

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200318

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200318

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200318

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200318

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200318

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200318

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20240509

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240507

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20240509

Year of fee payment: 14